# 2025年11月5日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 基于转录组学与3D成像技术的人类皮肤淋巴管系统特征研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41186588](https://pubmed.ncbi.nlm.nih.gov/41186588)
**期刊：** The Journal of experimental medicine
**PMID：** 41186588
**DOI：** 10.1084/jem.20242353

### 第一部分 原文与翻译

**英文原标题：** Transcriptomics- and 3D imaging-based characterization of the lymphatic vasculature in human skin.

**英文摘要原文：**
Afferent lymphatic vessels (LVs) are present in most vascularized tissues and exert important immune and drainage functions, yet human afferent LVs remain poorly studied. Performing single-cell RNA sequencing of lymphatic endothelial cells (LECs) from human skin and subcutaneous adipose tissue, we identified various LEC subsets, including two valve LEC populations located on the upstream and downstream sides of the valve leaflets. The cell adhesion molecule CD24 emerged as a specific marker of upper valve leaflet LECs in human skin and contributed to lymphatic valve development in murine mesentery. Three-dimensional imaging further revealed several unique features of the human dermal lymphatic network, including a high proportion of LYVE-1+ pre-collecting vessels containing intraluminal valves, virtually no collectors, and absence of lymphatic muscle cell coverage. Moreover, LECs in blind-ended capillaries and around valves in pre-collectors displayed mixed junctional and morphological phenotypes. These findings reveal key differences between human and murine dermal afferent lymphatics and provide a deeper understanding of human lymphatic-related (patho)physiological processes.

**中文摘要译文：**
传入淋巴管（LVs）存在于大多数有血管分布的组织中，并发挥着重要的免疫和引流功能，然而人类传入淋巴管的研究仍不充分。通过对来自人类皮肤和皮下脂肪组织的淋巴管内皮细胞（LECs）进行单细胞RNA测序，我们识别出了多种LEC亚群，包括位于瓣叶上游和下游的两个瓣膜LEC群体。细胞粘附分子CD24被发现是人类皮肤中上瓣叶LEC的特异性标志物，并参与了鼠类肠系膜淋巴管瓣膜的发育。三维成像进一步揭示了人类真皮淋巴网络的几个独特特征，包括高比例含有腔内瓣膜的LYVE-1+前集合淋巴管、几乎没有集合淋巴管以及缺乏淋巴管肌细胞覆盖。此外，位于盲端毛细淋巴管和前集合淋巴管瓣膜周围的LEC表现出混合的连接和形态表型。这些发现揭示了人类与鼠类真皮传入淋巴管之间的关键差异，并为深入理解人类淋巴相关的（病理）生理过程提供了基础。

### 第二部分 AI 大师评价

本研究创新性地结合了单细胞转录组学与3D成像技术，首次精细刻画了人类皮肤淋巴管系统的细胞和结构特征。其核心发现不仅识别出新的淋巴管内皮细胞亚群及瓣膜特异性标志物CD24，更揭示了人类与传统鼠类模型在淋巴网络结构上的显著差异。这项工作为理解人类淋巴系统的生理功能及其在淋巴水肿、肿瘤转移等疾病中的作用提供了关键的基础数据和新视角，具有重要的科研价值和临床启示意义。

---

## 2. AASLD/IDSA 慢性乙型肝炎治疗实践指南

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41186418](https://pubmed.ncbi.nlm.nih.gov/41186418)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41186418
**DOI：** 10.1097/HEP.0000000000001549

### 第一部分 原文与翻译

**英文原标题：** AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B.

**英文摘要原文：**
BACKGROUND AND AIMS: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach.

METHODS: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO questions covering prevention (maternal to infant transmission and horizontal transmission), surveillance for liver cancer (among hepatitis B surface antigen positive (HBsAg) persons co-infected with hepatitis C virus, hepatitis D virus and/or human immunodeficiency viruses and after HBsAg loss) and treatment (HBsAg positive persons in immune-tolerant or indeterminate phases as well as withdrawal of antiviral therapy), providing evidence-based recommendations on these topics. Four systematic reviews of the literature were conducted, and two existing systematic reviews were utilized to support the recommendations in this practice guideline.

CONCLUSIONS: This evidence-based guideline provides updated recommendations to optimize the care of persons with CHB.

**中文摘要译文：**
背景与目的：与慢性乙型肝炎（CHB）的预防、监测和治疗相关的累积数据为本指南的更新提供了动力，指南采用了推荐分级、评估、制定与评价（GRADE）方法。
方法：本指南的制定遵循了美国国家医学院的标准。指南专家组遵循“人群、干预、比较、结局”（PICO）框架制定了结构化问题。专家组解决了6个PICO问题，涵盖预防（母婴传播和水平传播）、肝癌监测（针对乙型肝炎表面抗原（HBsAg）阳性且合并感染丙型肝炎病毒、丁型肝炎病毒和/或人类免疫缺陷病毒者，以及HBsAg血清学转换后的患者）和治疗（处于免疫耐受期或不确定期的HBsAg阳性者以及抗病毒治疗的停药），并就这些主题提供了循证推荐。为支持本实践指南中的推荐，共进行了四项文献系统综述，并利用了两项现有的系统综述。
结论：本循证指南为优化慢性乙型肝炎患者的临床管理提供了更新的推荐意见。

### 第二部分 AI 大师评价

本指南由美国肝病研究学会（AASLD）和美国感染病学会（IDSA）联合发布，旨在基于最新的循证医学证据，为慢性乙型肝炎的临床管理提供权威指导。其核心价值在于系统性地运用GRADE和PICO框架，针对预防、监测和治疗中的六大关键临床问题，如特殊人群的肝癌监测和抗病毒治疗停药时机等，提出了明确的推荐意见。作为肝病与感染病领域的纲领性文件，该指南对于规范全球临床实践、优化患者管理策略具有重大意义，是临床医生处理复杂乙肝病例的重要参考依据。

---

## 3. 为2025年AASLD慢性乙型肝炎管理实践指南提供支持的技术性系统评价

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41186417](https://pubmed.ncbi.nlm.nih.gov/41186417)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41186417
**DOI：** 10.1097/HEP.0000000000001584

### 第一部分 原文与翻译

**英文原标题：** Technical systematic review supporting 2025 AASLD Practice Guidelines on management of chronic hepatitis B.

**英文摘要原文：**
BACKGROUND: With rapid changes in the management landscape of chronic hepatitis B (CHB), this technical systematic review addresses four critical Population, Intervention, Comparator, Outcome (PICO) questions to provide guidance to the formulation of recommendations to the 2025 AASLD practice guidelines for management of CHB.

METHODS: The review was reported in accordance with PRISMA guidelines. Outcomes were evaluated across four key PICOs: (1) antiviral therapy for prevention of horizontal HBV transmission in high-risk groups, (2) antiviral therapy versus observation for persons in the immune-tolerant phase, (3) discontinuation versus continuation of nucleos(t)ide analogue therapy in HBeAg-negative individuals with undetectable HBV DNA, and (4) hepatocellular carcinoma (HCC) surveillance in non-cirrhotic individuals with HBsAg clearance or co-infections with HCV, HDV, or HIV.

RESULTS: For PICO 1, limited evidence suggests antiviral therapy may reduce horizontal transmission risk, though with low certainty. PICO 2 analyses reveal uncertain benefits of treating persons in the immune-tolerant phase, with very low certainty due to heterogeneity and bias. PICO 3 analyses demonstrate that discontinuing antiviral therapy in persons who are HBeAg negative with undetectable HBV DNA increases HBsAg loss rates (OR 12.65, 95% CI 1.58-101.51) but carries moderate risks of virologic relapse (OR 47.17, 95% CI 2.79-797.35), and clinical flares. PICO 4 analyses on several cohort studies showed that in patients co-infected with HCV, HBV, or HIV, annual incidence of HCC was higher than the level where screening becomes cost-effective, suggesting that regular liver cancer screening could be beneficial for these patients.

CONCLUSIONS: Despite low certainty, the findings support shared decision-making in high-risk horizontal transmission scenarios or in treating individuals in the immune tolerance phase, caution in discontinuing antiviral therapy in virologically suppressed individuals without HBsAg loss, and tailored HCC surveillance for those with co-infection or cirrhosis.

**中文摘要译文：**
背景：随着慢性乙型肝炎（CHB）管理领域的快速变化，本技术性系统评价旨在解决四个关键的“人群、干预、对照、结局”（PICO）问题，为制定2025年AASLD慢性乙型肝炎管理实践指南的推荐意见提供指导。

方法：本评价遵循PRISMA指南进行报告。我们围绕四个关键PICO问题对结局进行了评估：（1）抗病毒治疗在高危人群中预防乙肝病毒水平传播的效果；（2）对处于免疫耐受期的患者采用抗病毒治疗与观察等待的比较；（3）在乙肝e抗原（HBeAg）阴性、乙肝病毒DNA（HBV DNA）检测不到的患者中，停用与继续使用核苷（酸）类似物治疗的比较；（4）在乙肝表面抗原（HBsAg）清除或合并丙肝病毒（HCV）、丁肝病毒（HDV）或人类免疫缺陷病毒（HIV）感染的非肝硬化患者中进行肝细胞癌（HCC）监测。

结果：对于PICO 1，有限的证据表明抗病毒治疗可能降低水平传播风险，但证据确定性较低。PICO 2的分析显示，治疗免疫耐受期患者的获益尚不确定，由于异质性和偏倚，证据确定性极低。PICO 3的分析表明，在HBeAg阴性且HBV DNA检测不到的患者中停用抗病毒治疗，可提高HBsAg清除率（OR 12.65, 95% CI 1.58-101.51），但伴随中等风险的病毒学复发（OR 47.17, 95% CI 2.79-797.35）和临床发作。PICO 4对几项队列研究的分析显示，在合并感染HCV、HDV或HIV的患者中，HCC的年发病率高于筛查具有成本效益的水平，提示对这些患者进行定期肝癌筛查可能是有益的。

结论：尽管证据确定性较低，研究结果仍支持在高风险水平传播情景下或治疗免疫耐受期患者时进行共同决策，在无HBsAg清除的病毒学抑制患者中谨慎停用抗病毒治疗，并对合并感染或肝硬化的患者进行个体化的HCC监测。

### 第二部分 AI 大师评价

本研究是一项为制定2025年美国肝病研究学会（AASLD）慢性乙型肝炎管理指南而进行的技术性系统评价。该研究采用PRISMA标准，围绕四个关键临床争议问题（PICO）进行证据梳理，包括抗病毒治疗的预防传播、免疫耐受期治疗、停药策略以及特殊人群的肝癌筛查。其核心发现强调了当前证据的局限性，例如免疫耐受期治疗的获益不确定，但在停药风险与获益、特殊人群肝癌筛查方面提供了量化依据。这项评价虽揭示了许多领域的证据质量不高，但其价值在于为即将更新的权威指南提供了最前沿的循证医学基础，直接指导临床实践中的复杂决策，并为未来的研究指明了方向。

---

## 4. 对《来自可生物降解镁植入物的气泡传递机械信号并促进免疫细胞刺激》一文的评论

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41186091](https://pubmed.ncbi.nlm.nih.gov/41186091)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41186091
**DOI：** 10.1002/advs.202518129

### 第一部分 原文与翻译

**英文原标题：** Comment on "Gas Bubbles From Biodegradable Magnesium Implants Convey Mechanical Cues and Promote Immune Cell Stimulation".

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文是一篇针对题为“来自可生物降解镁植入物的气泡传递机械信号并促进免疫细胞刺激”的原创性研究所发表的学术评论。该评论聚焦于可降解金属植入物领域的一个前沿话题，即镁降解产生的气泡所具有的生物学效应。学术评论在科学交流中扮演着至关重要的角色，它能够激发学术争鸣、澄清研究细节或对原有研究提出补充见解，从而推动该领域的深入发展。由于本文没有提供摘要，无法得知其具体评论观点，但其存在本身就凸显了原研究在学术界引起的重要反响和探讨价值。

---

## 5. Caspase激活后的继发性坏死可独立于Gasdermin E发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41185624](https://pubmed.ncbi.nlm.nih.gov/41185624)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41185624
**DOI：** 10.1002/advs.202507381

### 第一部分 原文与翻译

**英文原标题：** Secondary Necrosis Following Caspase-Activation can Occur Independently of Gasdermin E.

**英文摘要原文：**
Regulated necrosis is a known direct consequence of activation of the necroptosis- and pyroptosis- pathways, but may also result from apoptosis in a process referred to as secondary necrosis. Apoptosis is well understood to be mediated by caspase activation, but the mechanisms that lead to plasma membrane rupture in secondary necrosis remain considerably obscure. Recent data suggested a caspase-mediated cleavage of gasdermin E (GSDME), a member of the gasdermin family. Here, apoptosis induced by diphtheria toxin (DT) is employed as a novel tool to study secondary necrosis. In addition, cisplatin and anti-Fas monoclonal antibody Jo2 are employed to study secondary necrosis in cell culture and in vivo, respectively. Despite prominent, yet epiphenomenal cleavage of GSDME, it is demonstrated that silencing or CRISPR/Cas9-mediated knockout of GSDME does not compromise the kinetics of secondary necrosis induced by DT or cisplatin. During Jo2-induced acute liver toxicity in mice, GSDME expressed in the necrotic liver is detected predominantly in its uncleaved form. In conclusion, the hypothesis of GSDME to be a central mediator of secondary necrosis in these model systems is disproved.

**中文摘要译文：**
程序性坏死是众所周知的坏死性凋亡和焦亡通路激活的直接后果，但也可能由凋亡导致，这一过程被称为继发性坏死。众所周知，凋亡是由caspase激活介导的，但导致继发性坏死中质膜破裂的机制在很大程度上尚不清楚。近期数据显示，gasdermin家族成员之一的gasdermin E (GSDME) 可被caspase介导切割。本研究采用白喉毒素（DT）诱导的凋亡作为研究继发性坏死的新工具。此外，本研究还分别使用顺铂和抗Fas单克隆抗体Jo2在细胞培养和活体模型中研究继发性坏死。研究证明，尽管GSDME发生了显著的切割（但这仅为一种附带现象），沉默或通过CRISPR/Cas9介导的GSDME敲除并不会影响DT或顺铂诱导的继发性坏死的动力学过程。在Jo2诱导的小鼠急性肝毒性模型中，坏死肝脏中表达的GSDME主要以其未切割的形式被检测到。综上所述，本研究推翻了GSDME在这些模型系统中是继发性坏死核心介导者的假说。

### 第二部分 AI 大师评价

本研究旨在验证Gasdermin E (GSDME) 是否为caspase激活后继发性坏死的关键执行分子。研究者巧妙运用白喉毒素、顺铂及抗Fas抗体等多种模型，在细胞和动物水平上系统探究了GSDME的功能。核心发现是，无论通过基因沉默还是敲除GSDME，均不影响继发性坏死的进程，从而有力地驳斥了GSDME是该过程核心介导者的假说。这项工作澄清了细胞死亡领域的一个重要机制问题，其价值在于将研究焦点引向寻找继发性坏死真正的执行机制，对理解相关炎症及组织损伤病理过程具有重要意义。

---

## 6. 克服抗体药物偶联物的耐药性：从机制洞察到前沿策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41185045](https://pubmed.ncbi.nlm.nih.gov/41185045)
**期刊：** Journal of hematology & oncology
**PMID：** 41185045
**DOI：** 10.1186/s13045-025-01752-9

### 第一部分 原文与翻译

**英文原标题：** Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.

**英文摘要原文：**
Antibody-drug conjugates (ADCs) have revolutionized cancer therapy, but therapeutic resistance poses a significant barrier to sustained efficacy. Multiple mechanisms contribute to ADCs resistance, including drug efflux mediated by transporters, alterations in target antigens, tumor heterogeneity, and the impact of the tumor microenvironment (TME). Clinically, ADCs resistance varies across different cancer types, treatment lines, and patient subgroups. Emerging strategies now emphasize precision targeting through bispecific ADCs, alongside advancements in linker chemistry, payload design, and TME modulation. Additionally, rational combination therapies have emerged as a promising approach to reverse ADCs resistance, demonstrating synergistic effects. This review summarizes current understanding of mechanisms driving ADCs resistance and recent advances in combination therapies. By integrating mechanistic insights with emerging strategies, we aim to provide a comprehensive framework for addressing ADCs resistance and propose future research directions. These efforts may improve the efficacy of ADCs and the outcomes of cancer patients.

**中文摘要译文：**
抗体药物偶联物（ADC）彻底改变了癌症治疗，但治疗耐药性是其持续疗效的重大障碍。多种机制导致ADC耐药，包括转运蛋白介导的药物外排、靶抗原的改变、肿瘤异质性以及肿瘤微环境（TME）的影响。临床上，ADC的耐药性因癌症类型、治疗线数和患者亚组的不同而异。新兴策略现在强调通过双特异性ADC进行精准靶向，同时在连接子化学、有效载荷设计和TME调控方面也取得了进展。此外，合理的联合治疗已成为一种有前景的逆转ADC耐药性的方法，并显示出协同效应。本综述总结了目前对驱动ADC耐药性机制的理解以及联合治疗的最新进展。通过将机制洞察与新兴策略相结合，我们旨在为解决ADC耐药性问题提供一个全面的框架，并提出未来的研究方向。这些努力可能会提高ADC的疗效并改善癌症患者的预后。

### 第二部分 AI 大师评价

本篇综述系统性地阐述了抗体药物偶联物（ADC）耐药性的关键机制，并全面概述了为克服这一挑战而兴起的前沿策略。文章从药物外排、靶点改变、肿瘤异质性及微环境影响等多维度剖析了耐药性的成因，并重点介绍了双特异性ADC、优化药物设计及联合疗法等解决方案。该综述为理解和应对ADC耐药问题提供了宝贵的理论框架和实践指导，对于指导未来研究方向、开发新型ADC药物及优化临床治疗方案具有重要的参考价值。

---

## 7. 肺血管内皮PEAR1诱导肿瘤细胞休眠

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41185039](https://pubmed.ncbi.nlm.nih.gov/41185039)
**期刊：** Molecular cancer
**PMID：** 41185039
**DOI：** 10.1186/s12943-025-02488-3

### 第一部分 原文与翻译

**英文原标题：** Lung endothelial PEAR1 induces tumor cell dormancy.

**英文摘要原文：**
In many cancer patients, distant metastases develop after years of dormancy. Understanding how disseminated tumor cells (DTCs), which are often found in proximity to the microvasculature, remain dormant and what regulates their reactivation is one of the major challenges in tumor biology. In a screen for endothelial secreted and plasma membrane proteins able to regulate tumor cell dormancy, we identified the transmembrane protein platelet and endothelial aggregation receptor 1 (PEAR1). Human and murine endothelial cells lacking PEAR1 lost the ability to promote dormancy of different tumor cells, and the extracellular part of PEAR1 was able to rescue this effect. Similarly, in mice lacking PEAR1 in endothelial cells, tumor cell dormancy in the lung was reduced and tumor metastasis was increased. We found that PEAR1 induces tumor cell dormancy by binding lysyl oxidase like 2 (LOXL2) and cathepsin D (CTSD), which both inhibit tumor cell dormancy and promote tumor growth and metastasis. Tumor cells with suppressed CTSD expression showed increased dormancy and decreased metastatic potential in vivo. Our data identify a mechanism underlying tumor cell dormancy and suggest CTSD and LOXL2 as targets for approaches to promote dormancy.

**中文摘要译文：**
在许多癌症患者中，远处转移是在经历多年的休眠后发生的。理解那些常发现于微血管附近的播散性肿瘤细胞（DTCs）如何保持休眠状态，以及是什么调控它们的再激活，是肿瘤生物学领域的主要挑战之一。在一项旨在筛选能够调控肿瘤细胞休眠的内皮分泌蛋白和质膜蛋白的研究中，我们鉴定出了跨膜蛋白——血小板和内皮聚集受体1（PEAR1）。缺失PEAR1的人和小鼠内皮细胞失去了促进不同肿瘤细胞休眠的能力，而PEAR1的胞外部分能够挽救这一效应。同样地，在内皮细胞中缺失PEAR1的小鼠体内，肺部的肿瘤细胞休眠减少，而肿瘤转移则增加。我们发现PEAR1通过结合赖氨酰氧化酶样蛋白2（LOXL2）和组织蛋白酶D（CTSD）来诱导肿瘤细胞休眠，而LOXL2和CTSD这两种蛋白均会抑制肿瘤细胞休眠并促进肿瘤生长和转移。在体内实验中，CTSD表达被抑制的肿瘤细胞表现出增强的休眠状态和降低的转移潜能。我们的数据揭示了肿瘤细胞休眠的一个潜在机制，并提示CTSD和LOXL2可作为促进肿瘤休眠治疗策略的靶点。

### 第二部分 AI 大师评价

本研究旨在揭示血管内皮细胞调控肿瘤细胞休眠的关键机制。研究者通过蛋白筛选和功能实验，发现肺血管内皮细胞表达的PEAR1蛋白是诱导肿瘤细胞休眠的关键分子。其创新性在于，明确了PEAR1通过结合并抑制LOXL2和CTSD这两种促转移蛋白，从而维持肿瘤细胞的休眠状态。这一发现不仅为理解肿瘤休眠提供了新的分子视角，也为开发旨在预防肿瘤复发和转移的新型治疗策略（如靶向CTSD和LOXL2）提供了重要理论依据和潜在靶点。

---

## 8. 抗体药物偶联物在癌症治疗中的应用：研究现状、挑战与未来方向。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184856](https://pubmed.ncbi.nlm.nih.gov/41184856)
**期刊：** Molecular cancer
**PMID：** 41184856
**DOI：** 10.1186/s12943-025-02489-2

### 第一部分 原文与翻译

**英文原标题：** Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.

**英文摘要原文：**
Antibody-drug conjugates (ADCs) have emerged as a transformative modality in oncology by combining the target specificity of antibodies with the high potency of diverse cytotoxic payloads. This review provides an integrative overview of ADCs, spanning from molecular design to clinical translation. We dissect the structural components, antibodies, linkers, and payloads, and elucidate their impact on pharmacokinetics, tumor selectivity, and therapeutic index. Mechanistic pathways, including antigen recognition, receptor-mediated internalization, payload release, and immunogenic cell death (ICD), are highlighted to provide context for ADC function. Clinically, ADCs have demonstrated efficacy across hematologic and solid malignancies, with 15 Food and Drug Administration (FDA) approvals and an expanding investigational pipeline. However, challenges persist, including antigen heterogeneity, resistance mechanisms, systemic toxicities, and manufacturing complexities. Emerging innovations such as bispecific ADCs, immune-stimulatory payloads, AI-guided design, and nanotechnology-enhanced delivery are reshaping the ADC landscape. Finally, we emphasize the necessity of diagnostic precision and rational combination strategies, while highlighting emerging innovations that collectively shape the future direction of next-generation ADC therapeutics.

**中文摘要译文：**
抗体药物偶联物（ADCs）通过将抗体的靶点特异性与多种细胞毒性载荷的高效能相结合，已成为肿瘤学领域的一种变革性治疗模式。本综述对ADCs进行了全面的概述，涵盖了从分子设计到临床转化的全过程。我们深入剖析了其结构组成部分——抗体、连接子和载荷，并阐明了它们对药代动力学、肿瘤选择性和治疗指数的影响。文章重点介绍了其作用机制通路，包括抗原识别、受体介导的内化、载荷释放以及免疫原性细胞死亡（ICD），为理解ADC的功能提供了背景。在临床上，ADCs已在多种血液系统恶性肿瘤和实体瘤中显示出疗效，获得了15项美国食品药品监督管理局（FDA）的批准，并且其在研管线仍在不断扩大。然而，挑战依然存在，包括抗原异质性、耐药机制、全身性毒性以及生产制造的复杂性。双特异性ADC、免疫刺激性载荷、人工智能（AI）引导的设计以及纳米技术增强的递送等新兴创新正在重塑ADC领域的发展格局。最后，我们强调了精准诊断和合理联合策略的必要性，并重点介绍了共同塑造下一代ADC疗法未来发展方向的新兴创新。

### 第二部分 AI 大师评价

这篇综述系统性地概述了抗体药物偶联物（ADC）在癌症治疗中的应用。文章从ADC的分子设计、作用机制讲起，全面总结了其在临床应用中取得的成就和面临的耐药性、毒性等挑战。该文不仅是对当前ADC领域的全面梳理，更通过介绍双特异性ADC、AI辅助设计等前沿技术，深刻指出了下一代ADC疗法的发展方向，为相关领域的科研人员和临床医生提供了极具价值的参考。

---

## 9. 揭示人类基因组隐藏的编码潜力

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184642](https://pubmed.ncbi.nlm.nih.gov/41184642)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 41184642
**DOI：** 10.1038/s41580-025-00920-6

### 第一部分 原文与翻译

**英文原标题：** Revealing the hidden coding potential of the human genome.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

这篇发表于顶尖综述期刊的文章，旨在揭示人类基因组中长期被忽视的编码潜力。基于标题推断，本文可能系统性地总结了近年来利用核糖体分析、蛋白质组学和计算生物学等前沿技术，在发现和验证新型编码基因（如小开放阅读框）方面的突破性进展。该研究方向极具创新性，它不仅颠覆了对基因组编码能力的传统认知，更揭示了大量具有潜在生物学功能的新型微蛋白，为理解复杂疾病的遗传基础和开发新治疗靶点开辟了全新途径。

---

## 10. 更正：使用venetoclax联合布鲁顿酪氨酸激酶抑制剂对慢性淋巴细胞白血病进行固定疗程治疗：对伊布替尼与阿卡替尼差异的深入探讨

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184635](https://pubmed.ncbi.nlm.nih.gov/41184635)
**期刊：** Leukemia
**PMID：** 41184635
**DOI：** 10.1038/s41375-025-02793-2

### 第一部分 原文与翻译

**英文原标题：** Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

此文献是一篇更正启事，其本身不包含研究摘要，因此无法进行深入的科学评价。根据标题推断，其更正的原文旨在探讨使用venetoclax联合不同布鲁顿酪氨酸激酶抑制剂（伊布替尼与阿卡替尼）对慢性淋巴细胞白血病进行固定疗程治疗的差异。该研究方向具有重要的临床价值，旨在为临床医生在选择联合治疗方案时提供循证医学证据，以优化治疗效果并可能降低毒副作用。然而，此更正文献本身仅为修正原文中的错误，其价值在于确保学术记录的准确性。

---

## 11. ASXL1 C端截断与SRSF2突变通过免疫重编程驱动白血病发生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184634](https://pubmed.ncbi.nlm.nih.gov/41184634)
**期刊：** Leukemia
**PMID：** 41184634
**DOI：** 10.1038/s41375-025-02790-5

### 第一部分 原文与翻译

**英文原标题：** asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本研究旨在揭示ASXL1 C端截断和SRSF2突变在白血病发生中的协同作用机制。根据标题推断，其核心发现是这两种常见的基因突变通过重塑肿瘤免疫微环境来共同驱动白血病的恶性进展。这项工作的创新性在于，它明确指出了“免疫重编程”是连接特定基因型与白血病发生的关键生物学通路。尽管摘要缺失，无法获知具体实验细节，但该研究方向为理解骨髓肿瘤的发病机理提供了新视角，并可能为携带这些突变的患者开发新的免疫治疗策略提供理论基础。

---

## 12. 无创基因分型和早期疾病动态监测证实了伊布替尼联合免疫化疗在TRIANGLE试验中治疗套细胞淋巴瘤患者的疗效

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184633](https://pubmed.ncbi.nlm.nih.gov/41184633)
**期刊：** Leukemia
**PMID：** 41184633
**DOI：** 10.1038/s41375-025-02787-0

### 第一部分 原文与翻译

**英文原标题：** Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

**英文摘要原文：**
Adding ibrutinib to first-line immunochemotherapy (Ibru-R-chemo) showed superiority in younger mantle cell lymphoma (MCL) patients in the TRIANGLE trial (NCT02858258). To investigate response mechanisms and kinetics across treatment arms, we genotyped 57 patients from cell-free (cf)DNA using targeted-capture sequencing and investigated measurable residual disease (MRD) in cfDNA and peripheral blood by targeted-sequencing and qPCR. Pre-treatment cfDNA and circulating tumor (ct)DNA levels predicted outcomes, and precisely genotyped all patients. Circulating tumor cell (CTC)-clearance was more frequent and rapid than ctDNA-clearance across arms. At interim staging (IS), 55% of patients were ctDNA-positive while 35% and 41% were CTC-positive by qPCR and immunoglobulin gene (IG)-NGS. At end of induction, 43% were ctDNA-positive, while 15% (qPCR) and 25% (IG-NGS) were CTC-positive. MRD by qPCR was most predictive for outcomes. Ibru-R-chemo seemed to overcome TP53-mediated risk (hazard ratio 1.9 vs. 10) and induce early MRD response, represented by enhanced CTC (71% vs. 57%) and ctDNA clearance (59% vs. 24%) at IS. Flow-cytometry-based immunomonitoring showed ibrutinib's influence on inhibitory T-cell phenotypes, showing ≥25% reduction in PD1+ and PD1+ KLRG1+ CD4+-T-cells in four patients. Taken together, besides direct anti-B-cell efficacy, ibrutinib improves chemotherapy efficiency by reconstituting an effective immune system and enhancing immune cell control.

**中文摘要译文：**
在TRIANGLE试验（NCT02858258）中，一线免疫化疗（Ibru-R-chemo）中加入伊布替尼对年轻套细胞淋巴瘤（MCL）患者显示出优越性。为研究不同治疗组的反应机制和动力学，我们利用靶向捕获测序对57例患者的无细胞(cf)DNA进行了基因分型，并通过靶向测序和qPCR检测了cfDNA及外周血中的微小残留病（MRD）。治疗前的cfDNA和循环肿瘤(ct)DNA水平可预测预后，并能对所有患者进行精确的基因分型。在各治疗组中，循环肿瘤细胞（CTC）的清除比ctDNA的清除更频繁、更迅速。在中期分期（IS）时，55%的患者ctDNA呈阳性，而通过qPCR和免疫球蛋白基因（IG）-NGS检测，分别有35%和41%的患者CTC呈阳性。在诱导治疗结束时，43%的患者ctDNA呈阳性，而CTC阳性率分别为15%（qPCR）和25%（IG-NGS）。通过qPCR检测MRD对预后的预测价值最高。伊布替尼联合免疫化疗（Ibru-R-chemo）似乎能够克服TP53介导的风险（风险比为1.9 vs. 10），并诱导早期MRD反应，表现为中期分期时CTC清除率（71% vs. 57%）和ctDNA清除率（59% vs. 24%）的提高。基于流式细胞术的免疫监测显示，伊布替尼对抑制性T细胞表型有影响，在四名患者中观察到PD1+和PD1+ KLRG1+ CD4+ T细胞减少了≥25%。综上所述，除了直接的抗B细胞效力外，伊布替尼还通过重建有效的免疫系统和增强免疫细胞控制来提高化疗效率。

### 第二部分 AI 大师评价

本研究基于TRIANGLE临床试验，创新性地采用无创的液体活检技术，深入探究了伊布替尼联合免疫化疗一线治疗年轻套细胞淋巴瘤患者的疗效机制和反应动力学。研究核心发现，该联合方案不仅能更迅速、更深度地清除循环肿瘤DNA和肿瘤细胞，似乎还能克服TP53突变带来的不良预后。更重要的是，研究揭示了伊布替尼在直接抗肿瘤作用之外，还能通过调节T细胞表型、重塑免疫系统来增强化疗效果。这些发现为该联合方案的优越性提供了坚实的生物学证据，并凸显了ctDNA/MRD动态监测在指导MCL个体化治疗及预后判断中的巨大临床价值。

---

## 13. 干预肿瘤休眠以预防乳腺癌复发

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184538](https://pubmed.ncbi.nlm.nih.gov/41184538)
**期刊：** Nature reviews. Clinical oncology
**PMID：** 41184538
**DOI：** 10.1038/s41571-025-01087-x

### 第一部分 原文与翻译

**英文原标题：** Intervening on dormancy to prevent breast cancer recurrence.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该综述发表于顶尖期刊《自然综述：临床肿瘤学》，精准聚焦于乳腺癌治疗的核心挑战——复发。文章标题明确指出，其核心内容旨在探讨通过干预肿瘤细胞的“休眠”状态，作为预防乳腺癌复发的新策略。鉴于靶向休眠细胞是当前肿瘤学研究的前沿和难点，该文可能系统性地总结了相关分子机制、潜在的治疗靶点以及临床转化的前景与挑战，对于指导未来研究方向和开发新型治疗方案具有重要的理论价值和临床启示意义。

---

## 14. WBP11通过抑制UFL1介导的NONO蛋白UFM化修饰促进肝细胞癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184530](https://pubmed.ncbi.nlm.nih.gov/41184530)
**期刊：** Oncogene
**PMID：** 41184530
**DOI：** 10.1038/s41388-025-03620-9

### 第一部分 原文与翻译

**英文原标题：** WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression.

**英文摘要原文：**
Identification of novel targets is critical for the effective management of HCC. UFMylation, a novel ubiquitin-like modification, plays an important role in various biological processes and disease progression. We found that WW domain binding protein 11 (WBP11) is enriched and predicts poor prognosis in HCC. Depletion of WBP11 inhibits the malignancy of HCC cells in vitro and in vivo. Mechanistically, the N-terminal of WBP11 interacts with the RNA recognition motif (RRM) domain of Non-POU-domain-containing octamer-binding protein (NONO) and enhances glycolysis in HCC cells. WBP11 maintains protein stability of NONO by competitively inhibiting UFM1-specific ligase 1 (UFL1)-induced UFMylation of NONO at Lys198. Enforced-NONO expression restores the suppression of growth and metastasis caused by WBP11 depletion or UFL1 overexpression. Overall, our study identifies a key role of the WBP11-NONO axis in HCC progression and reveals the importance of UFMylation in cancer, highlighting potential anticancer strategies by targeting the WBP11-regulated new types of posttranslational modifications.

**中文摘要译文：**
识别新的治疗靶点对于肝细胞癌（HCC）的有效管理至关重要。UFM化（UFMylation）作为一种新型的泛素样修饰，在多种生物学过程和疾病进展中扮演着重要角色。我们发现，WW结构域结合蛋白11（WBP11）在肝细胞癌中富集，并预示着不良预后。在体外和体内实验中，敲低WBP11能够抑制肝细胞癌细胞的恶性行为。从机制上讲，WBP11的N末端与非POU结构域八聚体结合蛋白（NONO）的RNA识别基序（RRM）结构域相互作用，并增强肝细胞癌细胞的糖酵解作用。WBP11通过竞争性抑制UFM1特异性连接酶1（UFL1）诱导的NONO蛋白在赖氨酸198（Lys198）位点的UFM化修饰，来维持NONO的蛋白稳定性。强制表达NONO可以逆转由WBP11敲低或UFL1过表达所引起的生长和转移抑制效应。总而言之，我们的研究明确了WBP11-NONO轴在肝细胞癌进展中的关键作用，揭示了UFM化修饰在癌症中的重要性，并强调了通过靶向WBP11调控的新型蛋白质翻译后修饰来制定抗癌策略的潜力。

### 第二部分 AI 大师评价

本研究旨在阐明WBP11蛋白在肝细胞癌（HCC）进展中的作用及其分子机制。研究通过体内外实验发现，WBP11在HCC中高表达，并通过与NONO蛋白相互作用，竞争性抑制UFL1介导的NONO蛋白UFM化修饰，从而增强其稳定性并促进肿瘤细胞的糖酵解。此项工作的创新之处在于首次揭示了WBP11-NONO信号轴在调控HCC恶性进展中的关键角色，并阐明了UFM化这一新型翻译后修饰在其中的重要调控作用。该发现不仅深化了对HCC发病机制的理解，也为开发靶向该信号通路的抗癌新策略提供了重要的理论依据和潜在靶点。

---

## 15. 突变型p53蛋白的累积可被邻近诱导药物选择性靶向

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184486](https://pubmed.ncbi.nlm.nih.gov/41184486)
**期刊：** Nature chemical biology
**PMID：** 41184486
**DOI：** 10.1038/s41589-025-02051-7

### 第一部分 原文与翻译

**英文原标题：** Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs.

**英文摘要原文：**
TP53 mutant cancers are associated with approximately half of cancer deaths. The most common mechanism of p53 inactivation involves missense mutations. Such mutations in TP53 result in a robust upregulation of the p53 protein. Here, we demonstrate an induced proximity approach to selectively kill TP53 mutant cells. This approach uses the increased abundance of p53 protein in TP53 mutant cancer cells to concentrate toxic molecules in these cells. We demonstrate this approach with a molecule that binds the Y220C mutant of p53 and concentrates a PLK1 inhibitor in cells harboring TP53 mutations. The resulting bifunctional molecule promotes formation of a p53-PLK1 ternary complex, mislocalizes PLK1, inhibits PLK1 activity, elicits selective G2/M arrest and induces apoptosis in TP53 cells while sparing wild-type TP53 cells. These data exemplify a potentially generalizable framework for targeting TP53 missense mutations by leveraging mutant p53 protein abundance to induce cell death, independent of p53's transcriptional activity.

**中文摘要译文：**
TP53突变型癌症与约一半的癌症死亡相关。p53失活的最常见机制涉及错义突变。TP53中的此类突变导致p53蛋白的显著上调。在此，我们展示了一种利用诱导邻近策略选择性杀伤TP53突变细胞的方法。该方法利用TP53突变癌细胞中p53蛋白丰度的增加，将有毒分子富集于这些细胞内。我们通过一个能与p53的Y220C突变体结合、并在携带TP53突变的细胞中富集PLK1抑制剂的分子，验证了此方法。由此产生的双功能分子能促进p53-PLK1三元复合物的形成，使PLK1错误定位，抑制其活性，在TP53突变细胞中引发选择性的G2/M期阻滞并诱导细胞凋亡，同时对野生型TP53细胞无影响。这些数据例证了一个可能具有普适性的框架，即利用突变p53蛋白的高丰度来诱导细胞死亡，从而靶向TP53错义突变，且此过程不依赖于p53的转录活性。

### 第二部分 AI 大师评价

本研究旨在开发一种新策略，以选择性地靶向并清除携带TP53错义突变的癌细胞。研究者巧妙地设计了一种双功能分子，它利用突变型p53蛋白在癌细胞中的高丰度作为“锚点”，将PLK1抑制剂这类“毒性弹头”精准富集到肿瘤内部。关键发现是，这种诱导邻近的药物能有效抑制PLK1活性，导致突变细胞周期阻滞和凋亡，同时对正常细胞影响甚微。该研究的创新性在于将一个致病的蛋白高表达特征转化为一种可利用的治疗弱点，为靶向传统上“不可成药”的突变蛋白提供了全新且具有普适性的思路，展现了巨大的临床转化潜力。

---

## 16. 劫持突变型p53的丰度

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184485](https://pubmed.ncbi.nlm.nih.gov/41184485)
**期刊：** Nature chemical biology
**PMID：** 41184485
**DOI：** 10.1038/s41589-025-02054-4

### 第一部分 原文与翻译

**英文原标题：** Hijacking mutant p53 abundance.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要。

### 第二部分 AI 大师评价

本文献标题揭示了一项旨在调控关键癌症靶点——突变型p53蛋白丰度的前沿研究。尽管摘要缺失，但从“劫持”（Hijacking）一词可推断，该研究可能采用了一种创新的化学生物学策略，例如利用细胞内源性降解途径，来特异性地降低突变型p53的水平。该研究若能成功，将为靶向突变型p53的癌症治疗提供极具价值的新思路和潜在工具，其在肿瘤学领域的科研和临床转化价值值得高度期待。然而，由于缺乏具体摘要信息，其详细机制、应用范围及局限性尚不明确。

---

## 17. 可注射生物可吸收导电水凝胶用于多模式脑肿瘤电免疫疗法。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184309](https://pubmed.ncbi.nlm.nih.gov/41184309)
**期刊：** Nature communications
**PMID：** 41184309
**DOI：** 10.1038/s41467-025-65785-x

### 第一部分 原文与翻译

**英文原标题：** Injectable bioresorbable conductive hydrogels for multimodal brain tumor electroimmunotherapy.

**英文摘要原文：**
Current electrode technologies are too rigid for safe and effective delivery of electrotherapy in the brain, and patients with glioblastoma continue to face a devastating prognosis, with median survival stalled at 15 months despite intensive treatment with surgery, radiation, and chemotherapy. But these conventional approaches potentially compromise immune function, underscoring the urgent need for therapies that activate, rather than suppress, the immune system. Therefore, we introduce injectable conductive hydrogels engineered to match the softness of brain tissue while exhibiting electrical conductivities up to three orders of magnitude higher than any previously reported injectable hydrogels. They can be implanted through minimally invasive syringe capillaries as narrow as 30 µm-avoiding brain tissue damage-and via convection-enhanced delivery (CED) or endovascular catheters, the latter potentially eliminating the need for open brain surgery. Additionally, it can drape a resection cavity to eliminate residual tumor cells. In human glioblastoma tumors in the chicken chorioallantoic membrane model, implantation of the electrode using CED, followed by irreversible electroporation, obliterated tumors within three days. Other injection techniques impaired tumor growth, induced immunogenic cell death, and a robust infiltration of helper and cytotoxic T cells, alongside macrophages, highlighting the immune-activating and tumor-targeting capabilities.

**中文摘要译文：**
当前的电极技术过于刚硬，无法在脑内安全有效地实施电疗，而胶质母细胞瘤患者尽管接受了手术、放疗和化疗等强化治疗，但预后仍然严峻，中位生存期停滞在15个月。然而，这些传统方法可能会损害免疫功能，这凸显了对能够激活而非抑制免疫系统的疗法的迫切需求。因此，我们介绍一种可注射的导电水凝胶，其经过精心设计，能够匹配脑组织的柔软度，同时其电导率比任何先前报道的可注射水凝胶高出三个数量级。它们可以通过细至30微米的微创注射器毛细管进行植入——从而避免脑组织损伤——并且可以通过对流增强递送（CED）或血管内导管植入，后者可能无需开颅手术。此外，它还可以覆盖切除腔以消除残留的肿瘤细胞。在鸡胚绒毛尿囊膜模型中的人类胶质母细胞瘤肿瘤中，使用CED植入电极后进行不可逆电穿孔，可在三天内消融肿瘤。其他注射技术抑制了肿瘤生长，诱导了免疫原性细胞死亡，并引发了辅助性T细胞、细胞毒性T细胞以及巨噬细胞的强烈浸润，凸显了其免疫激活和肿瘤靶向能力。

### 第二部分 AI 大师评价

本研究旨在开发一种创新的可注射生物可吸收导电水凝胶，用于治疗恶性程度极高的胶质母细胞瘤。研究团队通过构建与脑组织柔软度相匹配且电导率极高的水凝胶，并利用微创方式将其递送至肿瘤部位。关键发现表明，该水凝胶不仅能通过不可逆电穿孔高效消融肿瘤，还能诱导强烈的免疫原性细胞死亡和免疫细胞浸润，实现“电免疫疗法”。这项技术巧妙地结合了物理消融与免疫激活，为突破传统脑肿瘤治疗瓶颈提供了极具前景的新策略，具有重大的临床转化潜力。

---

## 18. 一种基于VHL的无定形SMARCA2 PROTAC关键功能结构的测定

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184304](https://pubmed.ncbi.nlm.nih.gov/41184304)
**期刊：** Nature communications
**PMID：** 41184304
**DOI：** 10.1038/s41467-025-65478-5

### 第一部分 原文与翻译

**英文原标题：** Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC.

**英文摘要原文：**
Proteolysis targeting chimeras (PROTACs) enable degradation of disease-related proteins via E3 ligase recruitment. PROTACs often do not easily crystallize, and they are usually formulated in amorphous forms. Determining the key interactions that stabilize the solid drug forms is of high interest. Here, we determine the complete atomic-level structure of an amorphous Von Hippel-Lindau (VHL)-based SMARCA2 PROTAC (PROTAC 2) using nuclear magnetic resonance (NMR) crystallography. We find that PROTAC 2 is more disordered as compared to previously studied amorphous formulations, and that the three functional units of the molecule have distinct structural types. In contrast to smaller drug molecules, where intermolecular hydrogen bonding interactions were found to be the main stabilization mechanism for the amorphous solid form, for PROTAC 2 we postulate that, in analogy to glassy polymers, the main stabilization mechanism is the entropic contribution introduced by the overall flexibility, especially in the linker region of the molecule. We also note that the most populated conformations found in the amorphous form differ from those of bound PROTAC 2 in the ternary protein complex as determined via X-ray crystallography. Our results provide insight into key structural features that stabilize amorphous formulations, specifically for molecules that can target proteins previously considered undruggable.

**中文摘要译文：**
蛋白质水解靶向嵌合体（PROTACs）通过招募E3连接酶来降解与疾病相关的蛋白质。PROTACs通常不易结晶，因此常被制成无定形态。确定稳定这些固体药物形态的关键相互作用具有重要意义。本研究中，我们利用核磁共振（NMR）晶体学方法，测定了一种基于冯·希佩尔-林道蛋白（VHL）的无定形SMARCA2 PROTAC（PROTAC 2）的完整原子级结构。我们发现，与先前研究的无定形制剂相比，PROTAC 2的无序程度更高，并且该分子的三个功能单元具有不同的结构类型。与小分子药物（其无定形固体的稳定机制主要为分子间氢键相互作用）不同，我们推测PROTAC 2的主要稳定机制类似于玻璃态聚合物，是由分子整体柔性（尤其是连接子区域的柔性）所带来的熵贡献。我们还注意到，在无定形态中发现的主要构象与通过X射线晶体学测定的、在三元蛋白复合物中结合状态下的PROTAC 2的构象不同。我们的研究结果为稳定无定形制剂的关键结构特征提供了见解，特别是针对那些能够靶向既往被认为“不可成药”蛋白的分子。

### 第二部分 AI 大师评价

本研究聚焦于PROTAC药物的固体制剂开发挑战，创新性地运用核磁共振晶体学方法，成功解析了一种无定形VHL基SMARCA2 PROTAC的完整原子级结构。研究的关键发现揭示，与传统小分子药物依赖氢键稳定不同，该PROTAC分子的稳定性主要源于其柔性连接子带来的熵贡献，这为理解大分子药物的无定形态提供了新的物理化学视角。此外，研究还发现其固态构象与生物活性构象存在差异，这些发现对PROTACs及其他“不可成药”靶点药物的固体制剂开发具有重要的指导价值。

---

## 19. 人工智能驱动的空间细胞表型组学改善非小细胞肺癌的风险分层

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184299](https://pubmed.ncbi.nlm.nih.gov/41184299)
**期刊：** Nature communications
**PMID：** 41184299
**DOI：** 10.1038/s41467-025-65783-z

### 第一部分 原文与翻译

**英文原标题：** AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer.

**英文摘要原文：**
Risk stratification remains a critical challenge in non-small cell lung cancer patients for optimal therapy selection. In this study, we develop an artificial intelligence-powered spatial cellomics approach that combines histology, multiplex immunofluorescence imaging and multimodal machine learning to characterize the complex cellular relationships of 43 cell phenotypes in the tumor microenvironment in a real-world retrospective cohort of 1168 non-small cell lung cancer patients from two large German cancer centers. The model identifies cell niches associated with survival and achieves a 14% and 47% improvement in risk stratification in the two main non-small cell lung cancer subtypes, lung adenocarcinoma and squamous cell carcinoma, respectively, combining niche patterns with conventional cancer staging. Our results show that complex immune cell niche patterns identify potentially undertreated high-risk patients qualifying for adjuvant therapy. Our approach highlights the potential of artificial intelligence powered multiplex imaging analyses to better understand the contribution of the tumor microenvironment to cancer progression and to improve risk stratification and treatment selection in non-small cell lung cancer.

**中文摘要译文：**
对于非小细胞肺癌患者而言，风险分层以选择最佳治疗方案仍然是一项关键挑战。本研究中，我们开发了一种人工智能驱动的空间细胞组学方法，该方法结合了组织学、多重免疫荧光成像和多模态机器学习，在一个来自两个德国大型癌症中心的1168名非小细胞肺癌患者的真实世界回顾性队列中，描绘了肿瘤微环境中43种细胞表型的复杂细胞关系。该模型识别出与生存相关的细胞微环境，并在结合微环境模式与传统癌症分期后，分别使肺腺癌和鳞状细胞癌这两种主要非小细胞肺癌亚型的风险分层准确性提高了14%和47%。我们的研究结果表明，复杂的免疫细胞微环境模式能够识别出可能治疗不足、有资格接受辅助治疗的高风险患者。我们的方法凸显了人工智能驱动的多重成像分析在更好地理解肿瘤微环境对癌症进展的贡献，以及改善非小细胞肺癌风险分层和治疗选择方面的潜力。

### 第二部分 AI 大师评价

本研究旨在利用人工智能驱动的空间分析技术，为非小细胞肺癌（NSCLC）患者构建更精准的风险分层模型。研究团队创新性地整合了组织学、多重免疫荧光成像与多模态机器学习，深入解析了大规模临床队列中肿瘤微环境的复杂细胞互作网络。其关键发现是，特定的免疫细胞微环境模式能显著提升传统分期方法的预测效能，尤其在鳞癌亚型中，从而有效识别出可能因治疗不足而预后较差的高风险患者。这项工作不仅展示了AI在解读肿瘤复杂生态系统中的强大潜力，更为NSCLC的个体化治疗决策（如辅助治疗的选择）提供了重要的临床依据和新工具。

---

## 20. 以首创线粒体谷氨酰胺转运蛋白SLC1A5_var抑制剂靶向癌症的谷氨酰胺依赖性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184297](https://pubmed.ncbi.nlm.nih.gov/41184297)
**期刊：** Nature communications
**PMID：** 41184297
**DOI：** 10.1038/s41467-025-64730-2

### 第一部分 原文与翻译

**英文原标题：** Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var.

**英文摘要原文：**
The mitochondrial glutamine transporter SLC1A5_var plays a central role in the metabolic reprogramming of cancer cells by facilitating glutamine import into mitochondria for energy production and redox homeostasis. Despite its critical function, the development of effective and selective inhibitors targeting SLC1A5_var has remained a significant challenge. Here, we introduce iMQT_020, a selective allosteric inhibitor identified through structure-based screening. iMQT_020 disrupts the trimeric assembly of SLC1A5_var, causing metabolic crisis in cancer cells and selectively suppressing their growth. Mechanistically, iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism. Additionally, iMQT_020 treatment epigenetically upregulates PD-L1 expression, enhancing the efficacy of combination therapies with anti-PD-L1 immune checkpoint inhibitors. These findings highlight the therapeutic potential of targeting SLC1A5_var as a critical metabolic vulnerability in cancer and demonstrate that targeting allosteric interprotomer interactions is a novel and promising therapeutic strategy for cancer treatment.

**中文摘要译文：**
线粒体谷氨酰胺转运蛋白SLC1A5_var通过促进谷氨酰胺输入线粒体以用于能量生产和维持氧化还原稳态，在癌细胞的代谢重编程中发挥核心作用。尽管其功能至关重要，但开发靶向SLC1A5_var的有效且选择性的抑制剂一直是一项重大挑战。在此，我们介绍了一种通过基于结构的筛选而发现的选择性变构抑制剂——iMQT_020。iMQT_020能够破坏SLC1A5_var的三聚体组装，从而引发癌细胞的代谢危机，并选择性地抑制其生长。从机制上看，iMQT_020减少了谷氨酰胺的补给和氧化磷酸化过程，从而广泛地扰乱了癌症代谢。此外，iMQT_020治疗还能表观遗传学地上调PD-L1的表达，从而增强了其与抗PD-L1免疫检查点抑制剂联合治疗的疗效。这些发现凸显了靶向SLC1A5_var作为癌症关键代谢脆弱点的治疗潜力，并证明靶向变构的原聚体间相互作用是一种新颖且有前景的癌症治疗策略。

### 第二部分 AI 大师评价

本研究旨在针对癌细胞的谷氨酰胺代谢依赖性，开发一种靶向线粒体谷氨酰胺转运蛋白SLC1A5_var的首创抑制剂。研究团队通过基于结构的筛选，成功发现了一种名为iMQT_020的选择性变构抑制剂。关键发现表明，该抑制剂通过破坏SLC1A5_var的三聚体结构来扰乱癌细胞代谢并抑制其生长，同时还能上调PD-L1表达，从而与免疫检查点抑制剂产生协同抗癌效应。这项工作不仅首次验证了靶向SLC1A5_var的临床治疗潜力，也提出了一种通过干预蛋白间变构相互作用的新型抗癌策略，为癌症代谢疗法与免疫疗法的结合提供了重要理论依据。

---

## 21. 线粒体ABHD11抑制驱动固醇代谢以调节T细胞效应功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184294](https://pubmed.ncbi.nlm.nih.gov/41184294)
**期刊：** Nature communications
**PMID：** 41184294
**DOI：** 10.1038/s41467-025-65417-4

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function.

**英文摘要原文：**
α/β-hydrolase domain-containing protein 11 (ABHD11) is a mitochondrial hydrolase that maintains the catalytic function of α-ketoglutarate dehydrogenase (α-KGDH), and its expression in CD4 + T-cells has been linked to remission status in rheumatoid arthritis (RA). However, the importance of ABHD11 in regulating T-cell metabolism and function is yet to be explored. Here, we show that pharmacological inhibition of ABHD11 dampens cytokine production by human and mouse T-cells. Mechanistically, the anti-inflammatory effects of ABHD11 inhibition are attributed to increased 24,25-epoxycholesterol (24,25-EC) biosynthesis and subsequent liver X receptor (LXR) activation, which arise from a compromised TCA cycle. The impaired cytokine profile established by ABHD11 inhibition is extended to two patient cohorts of autoimmunity. Importantly, using murine models of accelerated type 1 diabetes (T1D), we show that targeting ABHD11 suppresses cytokine production in antigen-specific T-cells and delays the onset of diabetes in vivo in female mice. Collectively, our work provides pre-clinical evidence that ABHD11 is an encouraging drug target in T-cell-mediated inflammation.

**中文摘要译文：**
α/β-水解酶结构域蛋白11（ABHD11）是一种线粒体水解酶，可维持α-酮戊二酸脱氢酶（α-KGDH）的催化功能，其在CD4+ T细胞中的表达与类风湿关节炎（RA）的缓解状态有关。然而，ABHD11在调节T细胞代谢和功能中的重要性尚待探索。在本研究中，我们发现对ABHD11的药理学抑制能够减弱人类和小鼠T细胞的细胞因子产生。从机制上讲，ABHD11抑制作用的抗炎效应归因于24,25-环氧胆固醇（24,25-EC）生物合成的增加以及随后因三羧酸循环（TCA）受损而引发的肝X受体（LXR）激活。由ABHD11抑制所确立的细胞因子谱受损现象，在两个自身免疫性疾病患者队列中得到了验证。重要的是，通过使用加速型1型糖尿病（T1D）的小鼠模型，我们证明靶向ABHD11可抑制抗原特异性T细胞的细胞因子产生，并在雌性小鼠体内延缓糖尿病的发作。总而言之，我们的工作为ABHD11作为T细胞介导的炎症中一个有前景的药物靶点提供了临床前证据。

### 第二部分 AI 大师评价

本研究旨在探索线粒体水解酶ABHD11在调节T细胞代谢与功能中的作用及其在自身免疫性疾病中的治疗潜力。研究团队通过药理学抑制方法，结合代谢组学分析和1型糖尿病小鼠模型，揭示了抑制ABHD11能够扰动三羧酸循环，进而激活“24,25-环氧胆固醇-肝X受体”信号通路，最终削弱T细胞的效应功能。这项工作创新性地将线粒体代谢、固醇代谢与T细胞免疫调控联系起来，为T细胞介导的炎症性疾病（如类风湿关节炎和1型糖尿病）提供了ABHD11这一具有重要临床转化潜力的药物新靶点。

---

## 22. 转座子对灵长类基因组的入侵塑造了人类炎症增强子及对炎症性疾病的易感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184288](https://pubmed.ncbi.nlm.nih.gov/41184288)
**期刊：** Nature communications
**PMID：** 41184288
**DOI：** 10.1038/s41467-025-64690-7

### 第一部分 原文与翻译

**英文原标题：** Transposon invasion of primate genomes shaped human inflammatory enhancers and susceptibility to inflammatory diseases.

**英文摘要原文：**
Human inflammatory response reflects adaptive alteration of immune-cell regulatory elements during human evolution. Yet the impact of the deeper evolutionary history of these elements, within primate genomes reshaped by transposon expansions, remains unclear. Tracing sequence changes in human immune-cell enhancers back to macaque and analysing proinflammatory transcription factor binding, we show that primate-specific endogenous retroviruses and Alu transposons introduced functional NF-κB and IRF1 motifs, contributing most to the great-ape-specific pool. After the human-macaque split, these motifs tend to evolve toward higher predicted binding affinity. In modern humans, positive selection favoured alleles, often Alu-derived, that increase enhancer affinity for NF-κB, and Alu-containing enhancers are enriched in signatures of adaptation. Highly mutable, Alus disproportionately contribute to the pool of adaptive alleles, including at enhancers linked to inflammatory diseases. We propose that primate-specific transposons facilitated the evolution of inflammatory responses in great apes, with Alus shaping adaptive potential in modern humans.

**中文摘要译文：**
人类的炎症反应反映了在人类进化过程中免疫细胞调控元件的适应性改变。然而，在被转座子扩增重塑的灵长类基因组中，这些元件更深远的进化史所产生的影响尚不明确。通过将人类免疫细胞增强子的序列变化追溯至猕猴，并分析促炎转录因子的结合情况，我们发现灵长类特异性的内源性逆转录病毒和Alu转座子引入了功能性的NF-κB和IRF1基序，对类人猿特异性基序库的贡献最大。在人类与猕猴分化后，这些基序倾向于向着预测结合亲和力更高的方向进化。在现代人类中，正向选择偏好那些能够增加增强子对NF-κB亲和力的等位基因（通常来源于Alu），并且含有Alu的增强子富集了适应性信号。由于高度可变，Alu元件对适应性等位基因库的贡献尤为突出，其中包括与炎症性疾病相关的增强子。我们提出，灵长类特异性转座子促进了类人猿炎症反应的进化，而Alu元件则塑造了现代人类的适应性潜力。

### 第二部分 AI 大师评价

本研究通过追溯人类免疫细胞增强子在灵长类动物中的进化史，揭示了转座子在塑造人类炎症反应及相关疾病易感性中的关键作用。研究团队创新性地发现，灵长类特异性的内源性逆转录病毒和Alu转座子为基因组引入了功能性的NF-κB和IRF1转录因子结合基序，并在进化中受到正向选择，增强了炎症反应。这项工作不仅巧妙地将“垃圾DNA”与人类免疫系统的适应性进化联系起来，也为理解炎症性疾病的遗传基础提供了深刻的进化生物学视角，具有重要的科研价值。

---

## 23. 致癌性KRAS突变通过免疫相关调控网络和代谢重编程驱动免疫抑制。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184283](https://pubmed.ncbi.nlm.nih.gov/41184283)
**期刊：** Cell death & disease
**PMID：** 41184283
**DOI：** 10.1038/s41419-025-08101-1

### 第一部分 原文与翻译

**英文原标题：** Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming.

**英文摘要原文：**
The KRAS mutation represents the most prevalent oncogenic alteration observed in human cancers. Its primary role involves directly driving malignant tumor development and growth through the activation of downstream signaling pathways. Increasing evidence suggests that KRAS significantly affects the immune response of KRAS-mutant tumors by modulating immune-related signaling and inflammatory pathways. In addition to broadly regulating the KRAS-associated immune signaling, KRAS influences immune cell phenotype and function by triggering tumor metabolic pathways. Here, we reviewed the KRAS mutation-associated immune microenvironment features and discussed how KRAS remodels the immune microenvironment by regulating immune-related molecules, inflammatory factors, and multiple metabolic pathways, offering insights that could be useful for developing effective immune-responsive therapies for KRAS-mutant tumors.

**中文摘要译文：**
KRAS突变是人类癌症中最常见的致癌性改变。其主要作用是通过激活下游信号通路，直接驱动恶性肿瘤的发生与生长。越来越多的证据表明，KRAS通过调控免疫相关信号和炎症通路，显著影响KRAS突变型肿瘤的免疫反应。除了广泛调节KRAS相关的免疫信号外，KRAS还通过启动肿瘤代谢通路来影响免疫细胞的表型和功能。在此，我们综述了KRAS突变相关的免疫微环境特征，并探讨了KRAS如何通过调控免疫相关分子、炎症因子和多种代谢途径来重塑免疫微环境，从而为开发针对KRAS突变型肿瘤的有效免疫响应疗法提供见解。

### 第二部分 AI 大师评价

本文是一篇综述性文章，系统阐述了致癌性KRAS突变如何通过复杂的分子机制导致肿瘤免疫抑制。文章的核心观点是，KRAS不仅直接促进肿瘤生长，更通过调控免疫相关信号网络、炎症因子以及肿瘤代谢重编程，主动塑造了一个抑制性的免疫微环境。该综述整合了免疫调控与代谢重编程两大前沿领域，为理解KRAS突变肿瘤的免疫逃逸机制提供了全面的视角，并为开发靶向KRAS突变肿瘤的新型免疫疗法指明了重要方向，具有较高的科研和临床参考价值。

---

## 24. 复杂的从头结构变异是罕见病中一个被低估的病因。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184278](https://pubmed.ncbi.nlm.nih.gov/41184278)
**期刊：** Nature communications
**PMID：** 41184278
**DOI：** 10.1038/s41467-025-64722-2

### 第一部分 原文与翻译

**英文原标题：** Complex de novo structural variants are an underestimated cause of rare disorders.

**英文摘要原文：**
Complex de novo structural variants (dnSVs) are crucial genetic factors in rare disorders, yet their prevalence and characteristics in rare disorders remain poorly understood. Here, we conduct a comprehensive analysis of whole-genome sequencing data of 12,568 families, including 13,698 offspring with rare diseases, obtained as part of the UK 100,000 Genomes Project. We identify 1,870 dnSVs, constituting the largest dnSV dataset reported to date. Complex dnSVs (n = 158; 8.4%) emerge as the third most common type of SV, following simple deletions and duplications. We classify 65% of these complex dnSVs into 11 subtypes. Among probands with dnSVs (n = 1,696), 9% exhibit exon-disrupting pathogenic dnSVs associated with the probands' phenotype. Notably, 12% of exon-disrupting pathogenic dnSVs and 22% of de novo deletions or duplications previously identified by array-based or whole-exome sequencing methods are found to be complex dnSVs. We also find distinct genomic properties of de novo deletions depending on the parent of origin. This study highlights the importance of complex dnSVs in the cause of rare disorders and demonstrates the necessity of specific genomic analysis to avoid overlooking these variants.

**中文摘要译文：**
复杂的从头结构变异（dnSVs）是罕见病中的关键遗传因素，然而其在罕见病中的患病率和特征仍然知之甚少。在此，我们对作为英国十万基因组计划一部分的12568个家庭（包括13698名患有罕见病的后代）的全基因组测序数据进行了全面分析。我们识别出1870个dnSVs，构成了迄今为止报道的最大的dnSV数据集。复杂的dnSVs（n = 158; 8.4%）是继简单缺失和重复之后，第三种最常见的结构变异类型。我们将这些复杂的dnSVs中的65%分为11个亚型。在携带dnSVs的先证者（n = 1,696）中，9%的个体表现出与先证者表型相关的、破坏外显子的致病性dnSVs。值得注意的是，我们发现12%的破坏外显子的致病性dnSVs以及22%先前通过芯片或全外显子组测序方法识别的从头缺失或重复，实际上是复杂的dnSVs。我们还发现，从头缺失的基因组特性因其亲本来源而异。本研究强调了复杂的dnSVs在罕见病病因中的重要性，并证明了进行特定基因组分析以避免忽视这些变异的必要性。

### 第二部分 AI 大师评价

本研究基于迄今最大规模的从头结构变异（dnSV）数据集，系统揭示了复杂的从头结构变异（complex dnSVs）在罕见病中的重要性。研究通过对超万个家庭的全基因组数据进行分析，发现complex dnSVs是第三大常见的结构变异类型，且既往许多通过传统方法认定的简单变异实际上是复杂变异。此项发现不仅强调了全基因组测序在精准识别此类变异中的绝对优势，也为提升罕见病的基因诊断率提供了关键证据，提示临床需重视并采用专门的分析策略来捕获这些被低估的致病因素。

---

## 25. 一种用于昆虫不育技术的温敏性CRISPR-Cas12a系统

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184277](https://pubmed.ncbi.nlm.nih.gov/41184277)
**期刊：** Nature communications
**PMID：** 41184277
**DOI：** 10.1038/s41467-025-64685-4

### 第一部分 原文与翻译

**英文原标题：** A temperature-sensitive CRISPR-Cas12a system for sterile insect technique.

**英文摘要原文：**
The sterile insect technique (SIT) reduces population numbers by releasing sterile males that produce non-viable progeny. Specifically, CRISPR/Cas9-based precision-guided SIT (pgSIT) generates sterile males through genetic crosses of two transgenic lines: a Cas9 strain and a guide RNA (gRNA) strain targeting male sterility and female viability or infertility. However, pgSIT requires separate maintenance of the two lines and sorting to obtain sterile males, creating possible challenges for scaling. To overcome this, we propose using Cas12a nuclease, which is inoperative at lower temperatures but active at higher temperatures. Here, we develop a Cas12a-based pgSIT system involving a single strain containing both the Cas12a nuclease and gRNAs to induce male sterility and female lethality. This strain can be maintained as a mixed stock of both sexes and only activated by increasing temperature, producing sterile males after just one generation. By reducing the challenges that arise with maintaining two separate lines, this system could offer a scalable alternative for vector control in combating vector-borne diseases.

**中文摘要译文：**
昆虫不育技术（SIT）通过释放能产生无活力后代的不育雄性来降低种群数量。具体而言，基于CRISPR/Cas9的精确引导不育技术（pgSIT）通过两个转基因品系的遗传杂交来产生不育雄性：一个品系表达Cas9，另一个品系表达靶向雄性不育和雌性存活/不育的指导RNA（gRNA）。然而，pgSIT需要分别维持这两个品系，并进行筛选以获得不育雄性，这给规模化应用带来了潜在挑战。为克服这一问题，我们提出使用Cas12a核酸酶，该酶在较低温度下无活性，但在较高温度下具有活性。在此，我们开发了一种基于Cas12a的pgSIT系统，该系统涉及一个单一品系，该品系同时包含Cas12a核酸酶和gRNA，以诱导雄性不育和雌性致死。该品系可以作为雌雄混合种群进行维持，仅通过升高温度即可激活，从而在短短一代内产生不育雄性。通过减少维持两个独立品系所带来的挑战，该系统可为防治媒介传播疾病提供一种可规模化的替代方案。

### 第二部分 AI 大师评价

本研究旨在解决传统CRISPR-Cas9介导的昆虫不育技术（pgSIT）中需要分离饲养和筛选品系的难题，以提高其规模化应用的可行性。研究团队巧妙地利用了Cas12a核酸酶的温敏特性，构建了一个包含Cas12a和gRNA的单一转基因品系。其核心发现是，该系统可在低温下稳定传代，通过简单的升温处理即可激活，高效诱导雄性不育和雌性致死，从而仅需一代即可产生大量不育雄性。这项创新极大地简化了操作流程，为病媒生物的控制和相关传染病的防治提供了一种更具扩展性和成本效益的策略。

---

## 26. 系统性证据分级评估白癜风的多系统关联与风险

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184267](https://pubmed.ncbi.nlm.nih.gov/41184267)
**期刊：** Nature communications
**PMID：** 41184267
**DOI：** 10.1038/s41467-025-64653-y

### 第一部分 原文与翻译

**英文原标题：** Systematic evidence grading evaluates multisystemic associations and risks of vitiligo.

**英文摘要原文：**
Vitiligo, a chronic autoimmune skin disorder characterized by refractory depigmentation, has inconsistent associations with various biomarkers and diseases due to confounding factors. Here, we conduct a comprehensive umbrella review and comparative analysis to evaluate the validity and strength of evidence from observational studies on vitiligo. 103 meta-analyses and 150 Mendelian randomization (MR) analyses are included, spanning categories including cardiometabolism, cancer, autoimmune, dermatosis, psychiatry/neurology/senses, and biomarkers/lifestyle. Evidence grading reveals seven convincing meta-analysis findings: five factors (fasting blood glucose, Graves' disease, thyroid antibodies, cataracts, and glaucoma) are associated with an increased risk of vitiligo, while vitiligo is related to two conditions (a decreased risk of overall cancer and an increased risk of inflammatory bowel disease). Future similar research is unlikely to alter these findings according to fail-safe number. Among them, the protective effect of vitiligo on overall cancer risk is also supported by causal associations from MR evidence, indicating a reassuring cancer risk in vitiligo. This study establishes an evidence hierarchy for vitiligo, which may inform multidisciplinary management strategies.

**中文摘要译文：**
白癜风是一种以顽固性色素脱失为特征的慢性自身免疫性皮肤病，由于混杂因素的影响，其与多种生物标志物和疾病的关联尚不一致。在此，我们进行了一项全面的伞形综述和比较分析，以评估关于白癜风的观察性研究证据的有效性和强度。研究纳入了103项荟萃分析和150项孟德尔随机化（MR）分析，涵盖了心脏代谢、癌症、自身免疫、皮肤病、精神/神经/感觉、生物标志物/生活方式等多个类别。证据分级揭示了七项令人信服的荟萃分析发现：五个因素（空腹血糖、格雷夫斯病、甲状腺抗体、白内障和青光眼）与白癜风风险增加相关，而白癜风本身与两种情况相关（总体癌症风险降低和炎症性肠病风险增加）。根据失安全数判断，未来的类似研究不太可能改变这些发现。其中，白癜风对总体癌症风险的保护作用也得到了孟德尔随机化证据所揭示的因果关联的支持，表明白癜风患者的癌症风险状况是令人安心的。本研究为白癜风建立了一个证据层级，这可能为多学科管理策略的制定提供参考。

### 第二部分 AI 大师评价

本研究创新性地采用伞形综述和孟德尔随机化分析，对白癜风与多系统疾病及生物标志物的关联进行了全面的证据梳理与评级。其核心目的在于从海量且常有矛盾的观察性研究中，筛选出最可靠的关联，为临床实践提供高级别证据。研究不仅确证了白癜风与甲状腺疾病、眼病等风险的强关联，更通过因果推断证实了白癜风患者总体癌症风险的降低，这对患者管理和认知具有重要的临床价值。该研究建立的证据层级体系，为白癜风的多学科综合管理策略提供了坚实的科学基础，并指明了未来研究的方向。

---

## 27. 新生小鼠缺氧缺血性脑损伤会相继招募具有两极分化表型与功能的中性粒细胞

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184264](https://pubmed.ncbi.nlm.nih.gov/41184264)
**期刊：** Nature communications
**PMID：** 41184264
**DOI：** 10.1038/s41467-025-65517-1

### 第一部分 原文与翻译

**英文原标题：** Hypoxic-ischemic brain injury in neonatal mice sequentially recruits neutrophils with dichotomous phenotype and function.

**英文摘要原文：**
Neonatal encephalopathy caused by hypoxia-ischemia (HI) leads to a strong neutrophil infiltration. The long-held assumption that neutrophils act exclusively as tissue-damaging cells, is challenged by increasing evidence of a profound neutrophil heterogeneity. Here, we uncovered a pronounced phenotypical and functional diversification of neutrophils in neonatal mice depending on the disease stage. Neutrophil infiltration was biphasic, peaking 1 and 7 days after HI. Early brain-infiltrating neutrophils displayed a hyperactivated phenotype, whereas neutrophils at day 7 exhibited an angiogenic phenotype with high Siglec-F expression. Acute neutrophil depletion protected against neural cell death, associated with decreased hyperactivity in adolescent animals. Delayed neutrophil depletion impaired vascular and oligodendrocyte regeneration, resulting in exacerbated alterations of anxiety-related behavior and myelination deficits. These findings suggest a divergent function of neutrophils, with early neutrophils aggravating tissue damage and late neutrophils contributing to neurological recovery. The disease stage-dependent neutrophil diversification offers new possibilities to identify disease-stage-specific therapeutic targets.

**中文摘要译文：**
由缺氧缺血（HI）引起的新生儿脑病会导致大量的中性粒细胞浸润。长期以来，人们认为中性粒细胞只扮演组织损伤细胞的角色，但越来越多关于中性粒细胞存在显著异质性的证据对这一假设提出了挑战。在本研究中，我们揭示了新生小鼠体内的中性粒细胞会根据疾病阶段表现出显著的表型和功能多样化。中性粒细胞的浸润呈双相性，在HI后第1天和第7天达到峰值。早期浸润脑部的中性粒细胞表现为超活化表型，而在第7天出现的中性粒细胞则表现为具有高Siglec-F表达的促血管生成表型。急性中性粒细胞清除可保护神经细胞免于死亡，并与青春期动物的多动行为减少相关。而延迟清除中性粒细胞则会损害血管和少突胶质细胞的再生，从而加剧焦虑相关行为的改变和髓鞘形成缺陷。这些发现表明中性粒细胞的功能具有差异性，即早期中性粒细胞会加剧组织损伤，而晚期中性粒细胞则有助于神经功能恢复。这种依赖于疾病阶段的中性粒细胞多样化为识别特定疾病阶段的治疗靶点提供了新的可能性。

### 第二部分 AI 大师评价

本研究通过新生小鼠缺氧缺血性脑损伤模型，创新性地揭示了中性粒细胞在疾病不同阶段扮演着截然相反的角色。研究发现，早期浸润的中性粒细胞（第1天）具有促炎损伤作用，而晚期（第7天）的中性粒细胞则转变为促进血管和神经再生的修复表型。这一关键发现颠覆了中性粒细胞在脑损伤中纯属有害的传统观念，为开发针对新生儿脑病的时间窗特异性精准治疗策略（例如早期抑制、晚期促进）提供了重要的实验依据和新思路。

---

## 28. 结合临床试验与LYSA研究组的真实世界数据为80岁以上初治弥漫性大B细胞淋巴瘤患者构建合成对照组：一项用于创新性临床试验的可靠策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184256](https://pubmed.ncbi.nlm.nih.gov/41184256)
**期刊：** Blood cancer journal
**PMID：** 41184256
**DOI：** 10.1038/s41408-025-01374-x

### 第一部分 原文与翻译

**英文原标题：** Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.

**英文摘要原文：**
Patients over 80 years (≥80 y.o.) with newly diagnosed diffuse large B-cell lymphomas (DLBCL) are underrepresented in clinical trials (CT). Use of synthetic control arms (SCA) could help to build innovative comparative trials. With this analysis, we aim to demonstrate the clinical performance & use of such SCA. With data from both CT (LNH09-7B) and real-world (REALYSA), we built a mixed SCA composed of ≥80 y.o. patients with DLBCL in the first line of treatment. In order to display clinically meaningful results, we demonstrate how we can reproduce SENIOR results, a double-arm randomized CT, by switching the internal control arm with our newly built SCA. Patients between arms were balanced using a stabilized inverse probability of treatment weighting approach (sIPTW) based on propensity scores (PS), and the endpoint was overall survival (OS). All covariates included in PS were well balanced after weighting, and OS of Mixed SCA vs. SENIOR experimental arm were not statistically different, with a HR of 0.743 [0.494-1.118] (p = 0.1654). Use of SCA built only from real-world data (REALYSA) and sensitivity analyses using different missing data management methods didn't differ from the whole analysis. In newly diagnosed elderly DLBCL patients, the use of SCAs can mimic the control arm of an RCT and could be used to build comparative CT for elderly patients and come up with fast-innovative CTs.

**中文摘要译文：**
80岁以上（≥80岁）的新诊断弥漫性大B细胞淋巴瘤（DLBCL）患者在临床试验（CT）中的代表性不足。使用合成对照组（SCA）可能有助于构建创新性的比较性试验。通过本项分析，我们旨在展示这类合成对照组的临床性能与用途。我们利用来自临床试验（LNH09-7B）和真实世界（REALYSA）的数据，构建了一个由接受一线治疗的≥80岁DLBCL患者组成的混合合成对照组。为了展示具有临床意义的结果，我们通过将SENIOR研究（一项双臂随机临床试验）的内部对照组替换为我们新建的合成对照组，来论证我们如何能重现其研究结果。我们采用基于倾向性评分（PS）的稳定逆概率治疗加权（sIPTW）方法对两组患者进行均衡，并将总生存期（OS）作为终点。加权后，所有纳入倾向性评分的协变量均达到了良好平衡，混合合成对照组与SENIOR研究试验组的总生存期无统计学差异（HR为0.743 [0.494-1.118]，p=0.1654）。仅使用真实世界数据（REALYSA）构建合成对照组以及采用不同缺失数据处理方法进行的敏感性分析，其结果与整体分析无差异。对于新诊断的老年DLBCL患者，使用合成对照组可以模拟随机对照试验（RCT）的对照组，可用于为老年患者构建比较性临床试验，并加速创新性临床试验的开发。

### 第二部分 AI 大师评价

本研究旨在验证为临床试验中代表性不足的80岁以上弥漫性大B细胞淋巴瘤（DLBCL）患者构建合成对照组（SCA）的可行性。研究创新性地结合了临床试验和真实世界数据，通过倾向性评分加权法成功模拟并替换了一项关键随机对照试验（SENIOR研究）的内部对照组。核心发现是，该合成对照组与原试验的试验组在总生存期上无统计学差异，证明其能够可靠地模拟传统对照组。此方法学验证对于老年肿瘤学领域具有重要价值，为未来开展针对该特殊人群的单臂试验或加速创新疗法评估提供了可靠且高效的研究策略。

---

## 29. 采用开环连接子的位点特异性连接酶依赖性偶联技术可改善靶向HER2的ADC的安全性与稳定性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184255](https://pubmed.ncbi.nlm.nih.gov/41184255)
**期刊：** Nature communications
**PMID：** 41184255
**DOI：** 10.1038/s41467-025-64675-6

### 第一部分 原文与翻译

**英文原标题：** Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs.

**英文摘要原文：**
Most of current ADCs have the problems of heterogeneity and payload-mediated off-target toxicities due to random conjugation and unstable linker. Herein we apply site-specific ligase-dependent conjugation (LDC) for GQ1001 and GQ1005, where humanized anti-HER2 antibody is linked to DM1 and DXd, respectively, via stable ring-opening linker. GQ1001 exhibits HER2 expression-dependent activity (contrary to T-DM1), indicating decreased off-target toxicity. The biostability of GQ1001 and GQ1005 in plasma is more favorable, and pharmacokinetics and safety profiles are improved in cynomolgus-monkeys with decreased circulating free-toxin levels. GQ1001 and GQ1005 are effective in animal models against pretreated HER2-positive cancers insensitive to HER2-targeting and/or chemotherapeutic drugs. The efficacy of GQ1001 is supra-additively enhanced by tyrosine-kinase inhibitors or chemotherapy, with manageable toxicity. GQ1001 is efficacious in cancers resistant to T-DXd due to high ABCG2 expression. Together, the LDC technology and ring-opening linker improve the stability and safety in GQ1001 and GQ1005 for treating refractory HER2-positive cancers.

**中文摘要译文：**
目前大多数ADC由于随机偶联和不稳定的连接子而存在异质性和载荷介导的脱靶毒性问题。本研究中，我们应用位点特异性连接酶依赖性偶联技术（LDC）开发了GQ1001和GQ1005，它们分别通过稳定的开环连接子将人源化抗HER2抗体与DM1和DXd连接。GQ1001表现出HER2表达依赖性活性（与T-DM1相反），表明其脱靶毒性有所降低。GQ1001和GQ1005在血浆中表现出更优的生物稳定性，并且在食蟹猴模型中，其药代动力学和安全性特征得到改善，循环游离毒素水平降低。在动物模型中，GQ1001和GQ1005对既往接受过治疗且对靶向HER2药物和/或化疗药物不敏感的HER2阳性癌症有效。GQ1001的疗效可被酪氨酸激酶抑制剂或化疗超加和性增强，且毒性可控。对于因ABCG2高表达而对T-DXd耐药的癌症，GQ1001同样有效。综上所述，LDC技术和开环连接子提高了GQ1001和GQ1005的稳定性与安全性，为治疗难治性HER2阳性癌症提供了新的策略。

### 第二部分 AI 大师评价

本研究旨在解决当前抗体药物偶联物（ADC）普遍存在的异质性与脱靶毒性问题。研究人员创新性地采用位点特异性连接酶依赖性偶联（LDC）技术，并结合一种新型的稳定开环连接子，开发了两款靶向HER2的新型ADC（GQ1001和GQ1005）。关键发现表明，这两款新型ADC不仅在血浆中稳定性更高、安全性更好，还对多种经治的、甚至对现有标准疗法（如T-DXd）耐药的HER2阳性肿瘤模型展现出强大的抗肿瘤活性。该研究通过优化偶联技术和连接子，为开发更安全、更有效的ADC药物提供了重要策略，对攻克难治性HER2阳性肿瘤具有重要的临床转化潜力。

---

## 30. 非典型钙粘蛋白CELSR2通过WNT3A/β-catenin信号通路成为胶质瘤的治疗靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184253](https://pubmed.ncbi.nlm.nih.gov/41184253)
**期刊：** Cell death & disease
**PMID：** 41184253
**DOI：** 10.1038/s41419-025-08116-8

### 第一部分 原文与翻译

**英文原标题：** Atypical cadherin CELSR2 acts as a therapeutic target for glioma through WNT3A/β-catenin signaling.

**英文摘要原文：**
Glioma is the most common primary brain tumors and has a high recurrence and mortality rate after surgery. Most gliomas are of astrocytic origin. We recently demonstrated that Celsr2 is essential for injury-induced responses and functions of astrocytes, while its role in the development and treatment of gliomas remains unexplored. In this study, an increase of CELSR2 expression was identified in patient glioma samples and glioma cell lines, and higher levels of CELSR2 correlate with poorer patient survival as indicated by TCGA data. In cultured glioma cells, CELSR2 knockdown reduced proliferation and caused cell cycle arrest, which was further supported by proteomic analysis. CELSR2 knockdown inhibited Wnt/β-catenin signaling, and the effect could be reversed by activating β-catenin using GSK-3β inhibitor in glioma cells. WNT3A efficiently enhanced the proliferation of glioma cells and activated the downstream signaling, which were significantly compromised by CELSR2 knockdown. We developed magnetic nanoparticles loaded with CELSR2-siRNA, which suppressed tumor growth in glioma-inoculated nude mice. In conclusion, CELSR2 positively regulates glioma development through WNT3A/β-catenin signaling and inhibiting CESLR2 is a novel therapeutic strategy for gliomas.

**中文摘要译文：**
胶质瘤是最常见的原发性脑肿瘤，术后复发率和死亡率高。大多数胶质瘤起源于星形胶质细胞。我们最近的研究表明，Celsr2对损伤诱导的星形胶质细胞反应和功能至关重要，但其在胶质瘤发生发展和治疗中的作用尚不明确。本研究发现，在胶质瘤患者样本和胶质瘤细胞系中CELSR2的表达升高，并且TCGA数据显示，CELSR2的高表达与患者较差的生存率相关。在培养的胶质瘤细胞中，敲低CELSR2可减少细胞增殖并导致细胞周期停滞，这一点得到了蛋白质组学分析的进一步支持。敲低CELSR2可抑制Wnt/β-catenin信号通路，而在胶质瘤细胞中使用GSK-3β抑制剂激活β-catenin可以逆转这一效应。WNT3A能有效增强胶质瘤细胞的增殖并激活下游信号通路，而敲低CELSR2则显著削弱了这些作用。我们开发了负载CELSR2-siRNA的磁性纳米颗粒，该纳米颗粒在接种胶质瘤的裸鼠体内抑制了肿瘤的生长。总之，CELSR2通过WNT3A/β-catenin信号通路正向调控胶质瘤的发展，抑制CELSR2是治疗胶质瘤的一种新型治疗策略。

### 第二部分 AI 大师评价

本研究旨在探究非典型钙粘蛋白CELSR2在胶质瘤进展中的作用及其作为治疗靶点的潜力。研究综合运用了临床样本分析、体外细胞实验及体内动物模型，揭示了CELSR2通过WNT3A/β-catenin信号通路促进胶质瘤细胞增殖的关键机制。其核心发现是，CELSR2在胶质瘤中高表达且与不良预后相关，靶向抑制CELSR2能有效抑制肿瘤生长。这项研究不仅为胶质瘤的病理机制提供了新的见解，更创新性地提出并验证了一种基于纳米技术的CELSR2靶向治疗策略，具有重要的临床转化潜力。

---

## 31. KDM6A磷酸化通过抑制PER2赋予头颈部鳞状细胞癌（HNSCC）糖酵解脆弱性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184251](https://pubmed.ncbi.nlm.nih.gov/41184251)
**期刊：** Cell death & disease
**PMID：** 41184251
**DOI：** 10.1038/s41419-025-08130-w

### 第一部分 原文与翻译

**英文原标题：** KDM6A phosphorylation suppresses PER2 to confer a glycolytic vulnerability in HNSCC.

**英文摘要原文：**
As a key tumor suppressor, KDM6A plays critical roles in maintaining epigenetic homeostasis and suppressing tumorigenesis. However, the regulatory mechanisms controlling KDM6A activity in head and neck squamous cell carcinoma (HNSCC) are not well defined. In this study, we employed tissue microarray analysis of clinical specimens to identify Ser829 as a predominant phosphorylation site of KDM6A in HNSCC and other solid tumors. Using mass spectrometry and biochemical assays, we demonstrate that CDK1-mediated phosphorylation at Ser829 enhances KDM6A binding to SFN, leading to its nuclear export and functional inactivation. Integrated chromatin profiling and metabolic analyses revealed that phosphorylated KDM6A-pSer829 drives glycolytic reprogramming through H3K27Me3-dependent transcriptional silencing of PER2, ultimately promoting tumor growth in vitro and in vivo. These findings establish KDM6A post-translational modification as a pivotal regulator of metabolic adaptation in HNSCC progression, providing a potential therapeutic target for combating cancer through this epigenetic-metabolic axis.

**中文摘要译文：**
作为一种关键的肿瘤抑制因子，KDM6A在维持表观遗传稳态和抑制肿瘤发生中发挥着至关重要的作用。然而，在头颈部鳞状细胞癌（HNSCC）中调控KDM6A活性的机制尚不明确。在本研究中，我们通过对临床样本进行组织微阵列分析，鉴定出Ser829是KDM6A在HNSCC及其他实体瘤中的一个主要磷酸化位点。通过质谱和生物化学分析，我们证明了CDK1介导的Ser829位点磷酸化增强了KDM6A与SFN的结合，导致其核输出和功能失活。综合染色质分析和代谢分析显示，磷酸化的KDM6A-pSer829通过H3K27Me3依赖性的PER2转录沉默，驱动了糖酵解重编程，最终在体外和体内促进了肿瘤生长。这些发现确立了KDM6A的翻译后修饰作为HNSCC进展中代谢适应的关键调控因子，并为通过这一表观遗传-代谢轴抗击癌症提供了一个潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明关键抑癌基因KDM6A在头颈部鳞状细胞癌（HNSCC）中的调控机制。研究团队综合运用组织微阵列、质谱、生物化学及多组学分析等方法，发现CDK1介导的KDM6A磷酸化是其功能失活的关键。这一磷酸化修饰通过抑制PER2基因的表达，驱动了肿瘤细胞的糖酵解重编程，从而促进肿瘤生长。该研究的创新之处在于揭示了KDM6A翻译后修饰在调控肿瘤代谢中的新作用，并首次将表观遗传、细胞周期与肿瘤代谢联系起来，为HNSCC的治疗提供了基于“表观遗传-代谢轴”的潜在新靶点。

---

## 32. 抗炎性天然类固醇激素25(OH)D或可作为全反式维A酸治疗急性早幼粒细胞白血病分化综合征的补充疗法

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184249](https://pubmed.ncbi.nlm.nih.gov/41184249)
**期刊：** Cell death & disease
**PMID：** 41184249
**DOI：** 10.1038/s41419-025-08109-7

### 第一部分 原文与翻译

**英文原标题：** Anti-inflammatory 25(OH)D, a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia.

**英文摘要原文：**
Differentiation syndrome (DS) is a serious complication with an unclear pathogenesis that arises following all-trans retinoic acid (ATRA) or arsenic trioxide induction therapy in acute promyelocytic leukemia (APL). DS symptoms include pyrexia, respiratory compromise, increased body mass, fluid accumulation, pulmonary infiltrates, hypotension, tachycardia, edema, and sepsis. It can also affect the kidneys and the central nervous system. The standard treatment to counteract DS involves the temporary cessation of ATRA or arsenic trioxide treatment and the administration of high-dose steroids to mitigate the inflammatory response. If left untreated, DS can be fatal. Further research has revealed that the inability to promptly recognize intracranial hemorrhage (ICH) in patients with APL may result in lethal consequences, with the cytokine storm identified as the principal factor in this scenario as well. ATRA therapy is known to induce transglutaminase 2 (TG2), which functions as a catalyst for DS development. In this study, we used NB4 cell lines and cells from a human patient with APL to investigate the ex vivo effects of ATRA and 25(OH)D cotreatment on NF-κB-regulated luciferase reporter gene activity. ATRA alone substantially enhanced cellular NF-κB luciferase reporter gene activity, whereas 25(OH)D dose-dependently reduced this activity. During ATRA-initiated cell maturation, 25(OH)D, known as calcidiol, suppressed the mRNA expression of NF-κB (p65/p50) and Rel family members, as well as the expression of genes associated with increased NF-κB activity. 25(OH)D also inhibited the ATRA-induced production of cytokines (e.g., IL-8), including IL-1β, TNF-α, and MCP-1, associated with the "cytokine storm." Combined treatment with ATRA plus 25(OH)D reduced cellular phospho-p65 and transglutaminase 2 (TG2) levels and increased the level of inhibitor of Rel (IκB), thereby attenuating the cytokine storm. These findings provide a molecular interpretation for clinical DS and IHC observations and may support future exploration of ATRA plus 25(OH)D cotreatment as a therapy for APL.

**中文摘要译文：**
分化综合征（DS）是急性早幼粒细胞白血病（APL）患者在接受全反式维A酸（ATRA）或三氧化二砷诱导治疗后出现的一种严重并发症，其发病机制尚不明确。DS的症状包括发热、呼吸功能受损、体重增加、液体潴留、肺部浸润、低血压、心动过速、水肿和脓毒症。它还可能影响肾脏和中枢神经系统。应对DS的标准治疗方法包括暂停ATRA或三氧化二砷治疗，并给予大剂量类固醇以减轻炎症反应。若不加以治疗，DS可能是致命的。进一步的研究表明，未能及时识别APL患者的颅内出血（ICH）可能导致致命后果，而细胞因子风暴同样被认为是此情况下的主要因素。已知ATRA治疗会诱导转谷氨酰胺酶2（TG2）的表达，该酶是DS发展的催化剂。在本研究中，我们使用NB4细胞系和来自APL患者的细胞，在体外研究了ATRA与25(OH)D联合处理对NF-κB调控的荧光素酶报告基因活性的影响。单独使用ATRA显著增强了细胞内NF-κB荧光素酶报告基因的活性，而25(OH)D则以剂量依赖的方式降低了该活性。在ATRA启动的细胞成熟过程中，被称为骨化二醇的25(OH)D抑制了NF-κB（p65/p50）及其Rel家族成员的mRNA表达，以及与NF-κB活性增强相关的基因表达。25(OH)D还抑制了ATRA诱导的与“细胞因子风暴”相关的细胞因子（如IL-8、IL-1β、TNF-α和MCP-1）的产生。ATRA与25(OH)D联合治疗降低了细胞内磷酸化p65和转谷氨酰胺酶2（TG2）的水平，并提高了Rel抑制蛋白（IκB）的水平，从而减弱了细胞因子风暴。这些发现为临床上的DS和ICH观察提供了分子层面的解释，并可能支持未来探索将ATRA与25(OH)D联合治疗作为APL的一种治疗方案。

### 第二部分 AI 大师评价

本研究旨在探索天然类固醇激素25(OH)D作为全反式维A酸（ATRA）治疗急性早幼粒细胞白血病（APL）时所引发分化综合征（DS）的潜在辅助疗法。通过体外细胞实验，研究人员发现25(OH)D能够有效抑制ATRA激活的NF-κB信号通路，从而显著降低细胞因子风暴相关炎症因子的表达。此项研究的创新之处在于揭示了25(OH)D在分子水平上对抗DS的潜力，为开发更安全的APL治疗策略提供了重要的实验依据和新思路，尽管其临床效果尚需进一步验证。

---

## 33. 孤儿核受体4A1（NR4A1）和NR4A2是CD71的内源性调节因子，其配体可诱导乳腺癌的铁死亡

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184246](https://pubmed.ncbi.nlm.nih.gov/41184246)
**期刊：** Cell death & disease
**PMID：** 41184246
**DOI：** 10.1038/s41419-025-08143-5

### 第一部分 原文与翻译

**英文原标题：** Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 are endogenous regulators of CD71 and their ligands induce ferroptosis in breast cancer.

**英文摘要原文：**
Ferroptosis is an iron-dependent cell death pathway that involves multiple genes, including the transferrin receptor (TFRC/CD71), glutathione peroxidase 4 (GPX4) and cystine-glutamate antiporter (SLC7A11). This study is based on the hypothesis that orphan nuclear receptor 4A1 (NR4A1) and NR4A2 maintain low levels of ferroptosis in triple negative breast cancer (TNBC) cells and bis-indole derived (CDIM) compounds act as NR4A1/2 ligands that induce ferroptosis by enhancing CD71 expression. 1,1-Bis(3'-indolyl)-1-(3,5-disubstitutedphenyl)methane (DIM-3,5) analogs were investigated for their cytotoxicity and effects on NR4A1 and NR4A2 regulated genes and induction of ferroptosis. Several assays also determined enhanced lipoperoxidation, reactive oxygen species and malondialdehyde formation in TNBC cells. Knockdown of NR4A1, NR4A2, Sp1 and Sp4 was carried out by RNA interference. Molecular mechanisms of NR4A1/2-mediated regulation of CD71 expression were determined using CD71-luciferase promoter constructs, overexpression of Sp1 and chromatin immunoprecipitation (ChIP) assays. Initial studies show that DIM-3,5 analogs act as an inverse NR4A1/NR4A2 agonists that downregulate the pro-oncogenic responses/gene products regulated by both receptors in TNBC cells. DIM-3,5 analogs also induced ROS, malondialdehyde and lipoperoxide formation in TNBC cells, and this was accompanied by decreased expression of GPX4 and SLC7A11 and induction of CD71. Induction of CD71, an important biomarker of ferroptosis was observed after treatment of TNBC cells with DIM-3,5 analogs, knockdown of NR4A1, NR4A2, Sp1 or Sp4 demonstrating that induction of CD71 was coregulated by both receptors. Moreover, both promoter and ChIP analysis indicated that NR4A1 and NR4A2 acted as ligand-dependent cofactors of Sp1/4-mediated expression of CD71 in TNBC cells. Thus, CD71, a key biomarker of ferroptosis is an NR4A1/2/Sp regulated gene that can be directly targeted by DIM-3,5 inverse NR4A1/2 agonists to induce ferroptosis in TNBC cells.

**中文摘要译文：**
铁死亡是一种铁依赖性的细胞死亡途径，涉及多种基因，包括转铁蛋白受体（TFRC/CD71）、谷胱甘肽过氧化物酶4（GPX4）和胱氨酸-谷氨酸反向转运体（SLC7A11）。本研究基于以下假说：孤儿核受体4A1（NR4A1）和NR4A2在三阴性乳腺癌（TNBC）细胞中维持低水平的铁死亡，而双吲哚衍生物（CDIM）化合物作为NR4A1/2的配体，通过增强CD71的表达来诱导铁死亡。研究人员对1,1-二(3'-吲哚基)-1-(3,5-二取代苯基)甲烷（DIM-3,5）类似物的细胞毒性及其对NR4A1和NR4A2调控基因和铁死亡诱导的影响进行了探究。多项检测也确定了TNBC细胞中脂质过氧化、活性氧和丙二醛的生成增强。通过RNA干扰技术对NR4A1、NR4A2、Sp1和Sp4进行了敲低。利用CD71-荧光素酶启动子构建体、Sp1的过表达以及染色质免疫沉淀（ChIP）分析，阐明了NR4A1/2介导的CD71表达调控的分子机制。初步研究表明，DIM-3,5类似物作为NR4A1/NR4A2的反向激动剂，能下调TNBC细胞中由这两种受体调控的促癌反应/基因产物。DIM-3,5类似物还诱导了TNBC细胞中活性氧、丙二醛和脂质过氧化物的形成，并伴随着GPX4和SLC7A11表达的降低以及CD71的诱导。在用DIM-3,5类似物处理TNBC细胞，或敲低NR4A1、NR4A2、Sp1或Sp4后，均观察到铁死亡重要生物标志物CD71的诱导，这表明CD71的诱导受到这两种受体的共同调控。此外，启动子分析和ChIP分析均表明，在TNBC细胞中，NR4A1和NR4A2作为Sp1/4介导的CD71表达的配体依赖性辅因子。因此，作为铁死亡关键生物标志物的CD71是一个受NR4A1/2/Sp调控的基因，可被DIM-3,5类NR4A1/2反向激动剂直接靶向，从而在TNBC细胞中诱导铁死亡。

### 第二部分 AI 大师评价

本研究旨在揭示孤儿核受体NR4A1/NR4A2在三阴性乳腺癌（TNBC）铁死亡过程中的调控作用，并验证其配体（DIM-3,5类似物）的抗癌潜力。研究综合运用了基因敲低、启动子活性分析及染色质免疫沉淀等分子生物学技术，关键发现NR4A1/NR4A2作为Sp1/4转录因子的配体依赖性辅因子，内源性地抑制了铁死亡关键标志物CD71的表达。此研究的创新之处在于阐明了一条全新的“NR4A1/2-Sp-CD71”信号轴，为治疗难治性TNBC提出了靶向诱导铁死亡的新策略，具有重要的临床转化价值。

---

## 34. Hippo-YAP信号通路通过诱导FHL3表达促进肝细胞癌进展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184244](https://pubmed.ncbi.nlm.nih.gov/41184244)
**期刊：** Cell death & disease
**PMID：** 41184244
**DOI：** 10.1038/s41419-025-08117-7

### 第一部分 原文与翻译

**英文原标题：** The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.

**英文摘要原文：**
The Hippo pathway plays an important role in cell proliferation, differentiation, and cancer occurrence. Yes-associated protein 1 (YAP) is a key effector molecule of Hippo pathway. Previous studies have found abnormal YAP overexpression in many solid tumors, including hepatocellular carcinoma (HCC). Here, we attempt to explore the cancer-promoting mechanism of YAP in HCC. The target gene of Hippo-YAP pathway, Four and a half LIM domain protein 3 (FHL3), was screened by spontaneous hydrodynamic tumor model with YAP participation and two publicly HCC microarray sets. Western blot (WB) and immunohistochemical (IHC) showed high protein levels of FHL3 in tumor tissues and the expression of FHL3 was associated with poorer prognosis. The biological effect experiments showed that FHL3 significantly promoted the progression of HCC. FHL3 interacted with MYC-associated zinc finger protein (MAZ) to recruit MAZ binding to the G-quadruplexes (G4s) structure, which promoted Kirsten rat sarcoma viral oncogene homologue (KRAS) transcription and activation of its downstream signal. Down-regulating KRAS expression inhibited the promoting effect of YAP-FHL3 signaling on HCC. In addition, transactivation of FHL3 mediated by YAP was verified by luciferase reporter assay and chromatin immunoprecipitation (ChIP). FHL3 knockdown inhibited the tumor-promoting effect of YAP and significantly delayed the tumorigenesis and progression caused by YAP. Finally, clinical data validated the correlation between YAP, FHL3, and KRAS expression. In conclusion, we identified a new target of Hippo-YAP signaling, FHL3, which interacts with MAZ to promote KRAS transcription and downstream oncogenic signaling pathway activation, thereby promoting HCC progression.

**中文摘要译文：**
Hippo通路在细胞增殖、分化和癌症发生中扮演着重要角色。Yes相关蛋白1（YAP）是Hippo通路的关键效应分子。既往研究发现，在包括肝细胞癌（HCC）在内的多种实体瘤中存在YAP的异常过表达。在此，我们试图探究YAP在肝细胞癌中的促癌机制。通过YAP参与的自发性水动力学肿瘤模型和两个公开的HCC微阵列数据集，我们筛选出了Hippo-YAP通路的目标基因——四叶半LIM结构域蛋白3（FHL3）。蛋白质印迹（WB）和免疫组织化学（IHC）结果显示，FHL3在肿瘤组织中呈高蛋白水平表达，且其表达与较差的预后相关。生物学效应实验表明，FHL3显著促进了肝细胞癌的进展。FHL3与MYC相关锌指蛋白（MAZ）相互作用，招募MAZ结合至G-四链体（G4s）结构，从而促进了Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）的转录及其下游信号的激活。下调KRAS的表达抑制了YAP-FHL3信号对肝细胞癌的促进作用。此外，通过荧光素酶报告基因实验和染色质免疫沉淀（ChIP）实验验证了YAP介导的FHL3的反式激活作用。敲低FHL3抑制了YAP的促瘤效应，并显著延缓了由YAP引起的肿瘤发生与进展。最后，临床数据验证了YAP、FHL3和KRAS表达之间的相关性。总而言之，我们鉴定出了Hippo-YAP信号传导的一个新靶点FHL3，它通过与MAZ相互作用来促进KRAS的转录和下游致癌信号通路的激活，从而促进肝细胞癌的进展。

### 第二部分 AI 大师评价

本研究旨在阐明Hippo-YAP信号通路在肝细胞癌（HCC）中的促癌机制。研究者通过动物模型与公开数据库筛选，结合一系列分子生物学实验，鉴定出FHL3是YAP的一个新型下游靶点。其核心发现是，YAP通过诱导FHL3表达，进而招募MAZ蛋白促进关键癌基因KRAS的转录，从而激活下游信号通路，驱动HCC进展。这项工作创新性地揭示了“YAP-FHL3-MAZ-KRAS”这一全新的信号转导轴，不仅深化了对HCC发病机理的理解，也为开发靶向治疗新策略提供了重要的理论依据和潜在分子靶点。

---

## 35. 通过招募FBXO22发挥作用的高效SMARCA2/A4小分子降解剂的理性设计

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184243](https://pubmed.ncbi.nlm.nih.gov/41184243)
**期刊：** Nature communications
**PMID：** 41184243
**DOI：** 10.1038/s41467-025-64669-4

### 第一部分 原文与翻译

**英文原标题：** Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22.

**英文摘要原文：**
Target-anchored monovalent degraders are more drug-like than their bivalent counterparts, Proteolysis Targeting Chimeras (PROTACs), while offering greater target specificity control than E3 ligase-anchored monovalent degraders, also known as molecular glues. However, their discovery has typically been serendipitous, and the rules governing their identification remain unclear. This study focuses on the intentional discovery of SMARCA2/A4 monovalent degraders using a library based on SMARCA2/A4 bromodomain-binding ligands. Compound G-6599 emerged as a lead candidate, showing exceptional degradation potency and specificity for SMARCA2/A4. Mechanistic studies reveal that G-6599 operates through the ubiquitin-proteasome pathway and the E3 ligase FBXO22. G-6599 promotes ternary complex formation between SMARCA2 and FBXO22 involving covalent conjugation to a cysteine residue on the latter. Unlike other recently identified FBXO22-dependent degraders, it does not require biotransformation. The selective degradation ability of G-6599, along with its unique mechanism, highlights the therapeutic potential of target-anchored monovalent degraders.

**中文摘要译文：**
与双价对应物——蛋白水解靶向嵌合体（PROTACs）相比，靶点锚定的单价降解剂具有更优的类药性；同时，与E3连接酶锚定的单价降解剂（又称分子胶）相比，它能提供更强的靶点特异性控制。然而，这类分子的发现通常是偶然的，且其鉴定规律尚不明确。本研究聚焦于利用一个基于SMARCA2/A4溴结构域结合配体的化合物库，来主动发现SMARCA2/A4单价降解剂。化合物G-6599作为一个先导候选物脱颖而出，对SMARCA2/A4表现出卓越的降解效力和特异性。机制研究表明，G-6599通过泛素-蛋白酶体途径和E3连接酶FBXO22发挥作用。G-6599通过与FBXO22上的一个半胱氨酸残基发生共价结合，从而促进SMARCA2和FBXO22之间形成三元复合物。与其他近期发现的依赖FBXO22的降解剂不同，它无需生物转化。G-6599的选择性降解能力及其独特机制，凸显了靶点锚定单价降解剂的治疗潜力。

### 第二部分 AI 大师评价

本研究成功展示了一种靶点锚定单价降解剂的理性设计策略，突破了该领域以往依赖偶然发现的局限。通过筛选配体库，研究团队发现了一种高效、特异性降解SMARCA2/A4的小分子G-6599。其关键创新在于揭示了G-6599通过共价结合方式招募非经典的E3连接酶FBXO22，且无需生物转化即可生效，这一独特机制为开发类药性更优的靶向蛋白降解疗法开辟了新路径，在肿瘤治疗等领域具有重要的科研与临床转化潜力。

---

## 36. 奥雷巴替尼，一种调节脂质代谢的多激酶抑制剂，用于治疗晚期琥珀酸脱氢酶缺陷型胃肠道间质瘤：一项1b期研究与转化研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184234](https://pubmed.ncbi.nlm.nih.gov/41184234)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41184234
**DOI：** 10.1038/s41392-025-02456-9

### 第一部分 原文与翻译

**英文原标题：** Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research.

**英文摘要原文：**
Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are generally resistant to targeted therapy with tyrosine kinase inhibitors (TKIs), such as imatinib, and there are no standard therapeutic options for advanced SDH-deficient GISTs. The precise oncogenic mechanisms of SDH mutations in GIST have not been elucidated. Olverembatinib, a novel multikinase inhibitor, has shown promising activity in treating imatinib-resistant GIST. We conducted a phase 1 study (NCT03594422) to evaluate the safety and antitumor activity of olverembatinib in 66 patients with unresectable/metastatic GIST/other solid tumors, including 26 with TKI-failed SDH-deficient GISTs. To our knowledge, this is the largest prospective clinical trial for this rare GIST subtype. The median follow-up was 14.5 (0.9-57.5) months. Olverembatinib was well tolerated; treatment-emergent adverse events (≥20%) included increases in hepatic transaminases, increases in leukocytes and neutrophils, anemia, and pyrexia. For SDH-deficient GISTs, confirmed partial responses were observed in 6 of the 26 evaluable patients (objective response rate, 23.1%; 95% CI, 9-43.7); an additional 16 (61.5%) did not progress during the first 6 months of treatment. This resulted in a clinical benefit rate of 84.6% (95% CI, 65.1-95.6), and the median progression-free survival was 25.7 months (95% CI, 12.9-NR). As a putative mechanism of action, translational research revealed significant lipid enrichment with the overexpression of lipid uptake-related genes and proteins, including CD36, fatty acid binding proteins, fatty acid transport proteins, and lipid metabolites, in SDH-deficient GIST patients, and olverembatinib suppressed lipid uptake and CD36 expression in GIST cells. Olverembatinib also exerts antitumor effects by inhibiting tumorigenic signaling pathways associated with hypoxia, angiogenesis, proliferation, and survival.

**中文摘要译文：**
琥珀酸脱氢酶（SDH）缺陷型胃肠道间质瘤（GISTs）通常对酪氨酸激酶抑制剂（TKIs）如伊马替尼的靶向治疗耐药，并且对于晚期SDH缺陷型GISTs尚无标准治疗方案。GIST中SDH突变的精确致癌机制尚未阐明。奥雷巴替尼是一种新型多激酶抑制剂，在治疗伊马替尼耐药的GIST中显示出有前景的活性。我们开展了一项1期研究（NCT03594422），旨在评估奥雷巴替尼在66名不可切除/转移性GIST/其他实体瘤患者中的安全性与抗肿瘤活性，其中包括26名经TKI治疗失败的SDH缺陷型GIST患者。据我们所知，这是针对这一罕见GIST亚型的最大规模的前瞻性临床试验。中位随访时间为14.5（0.9-57.5）个月。奥雷巴替尼的耐受性良好；治疗期间出现的不良事件（≥20%）包括肝转氨酶升高、白细胞和中性粒细胞增多、贫血及发热。对于SDH缺陷型GIST，在26名可评估患者中，有6名观察到经确认的部分缓解（客观缓解率23.1%；95% CI, 9-43.7）；另有16名（61.5%）在治疗的前6个月内疾病未进展。这使得临床获益率达到84.6%（95% CI, 65.1-95.6），中位无进展生存期为25.7个月（95% CI, 12.9-NR）。作为一种推定的作用机制，转化研究揭示，在SDH缺陷型GIST患者中存在显著的脂质富集，伴随脂质摄取相关基因和蛋白（包括CD36、脂肪酸结合蛋白、脂肪酸转运蛋白和脂质代谢物）的过表达，而奥雷巴替尼能抑制GIST细胞的脂质摄取和CD36表达。奥雷巴替尼还通过抑制与缺氧、血管生成、增殖和生存相关的致瘤信号通路来发挥抗肿瘤作用。

### 第二部分 AI 大师评价

本研究旨在评估新型多激酶抑制剂奥雷巴替尼在治疗标准疗法耐药的晚期SDH缺陷型胃肠道间质瘤（GIST）中的安全性和有效性。通过一项1b期临床试验及转化研究，该研究不仅证实了奥雷巴替尼具有良好的耐受性和显著的临床获益（临床获益率84.6%），为这一罕见肿瘤亚型提供了极具前景的治疗选择。更具创新性的是，研究首次揭示了SDH缺陷型GIST存在脂质代谢重编程的特征，并阐明奥雷巴替尼可通过抑制脂质摄取等多种途径发挥抗肿瘤作用，为理解该疾病的致病机理和开发新疗法提供了重要见解。

---

## 37. m6A去甲基化酶FTO通过重塑PFKM介导的糖酵解驱动胰腺导管腺癌的肿瘤发生与转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184232](https://pubmed.ncbi.nlm.nih.gov/41184232)
**期刊：** Cell death & disease
**PMID：** 41184232
**DOI：** 10.1038/s41419-025-08049-2

### 第一部分 原文与翻译

**英文原标题：** mA demethylase FTO drives pancreatic ductal adenocarcinoma tumorigenesis and metastasis through remodeling PFKM mediated glycolysis.

**英文摘要原文：**
N6-methyladenosine (mA) modification has emerged as a common chemical modification in epigenetic regulation. However, whether this mA modification is involved in glycolysis metabolism in pancreatic ductal adenocarcinoma (PDAC) remains elusive. Multiomics integration strategies, including metabolomics, mA-seq and transcriptome sequencing, were utilized to evaluate the associations between mA modifications and key processes of glucose metabolism in PDAC. Spontaneous PDAC mice (LSLKras, LSL-Trp53, Pdx1-Cre; KPC) with FTO-conditional knockout and organoids were used to evaluate the effects of FTO stimulation on PDAC cell glycolysis and tumorigenesis. Series of in vivo and vitro functional analysis revealed that FTO promoted migratory capacity and glycolysis of PDAC cells. Mechanistically, FTO elevates the mRNA expression of the transcription factor C-Jun in a mA-YTHDF2-dependent manner and further transcriptionally upregulates PFKM expression. Translational studies involving organoid models and xenograft tumor models revealed that the use of FTO inhibitors significantly suppressed PDAC growth. Our findings uncover that targeting the mA-dependent FTO/C-Jun/PFKM glycolysis regulatory axis may be essential for the prevention and treatment of PDAC.

**中文摘要译文：**
N6-甲基腺苷 (m6A) 修饰已成为表观遗传调控中一种常见的化学修饰。然而，这种m6A修饰是否参与胰腺导管腺癌 (PDAC) 的糖酵解代谢仍不清楚。本研究利用了包括代谢组学、m6A-seq和转录组测序在内的多组学整合策略，以评估m6A修饰与PDAC中葡萄糖代谢关键过程之间的关联。研究使用了FTO条件性敲除的自发性PDAC小鼠 (LSLKras, LSL-Trp53, Pdx1-Cre; KPC) 和类器官模型，来评估FTO刺激对PDAC细胞糖酵解和肿瘤发生的影响。一系列体内外功能分析表明，FTO能够促进PDAC细胞的迁移能力和糖酵解过程。从机制上讲，FTO以m6A-YTHDF2依赖的方式提高转录因子C-Jun的mRNA表达，并进一步在转录水平上调PFKM的表达。涉及类器官模型和异种移植肿瘤模型的转化研究表明，使用FTO抑制剂可显著抑制PDAC的生长。我们的研究结果揭示，靶向m6A依赖的FTO/C-Jun/PFKM糖酵解调控轴可能对PDAC的预防和治疗至关重要。

### 第二部分 AI 大师评价

本研究旨在揭示m6A去甲基化酶FTO在胰腺导管腺癌（PDAC）进展中，特别是在调控糖酵解代谢方面的作用机制。研究团队综合运用了多组学分析、基因工程小鼠模型及类器官等前沿技术，系统地阐明了其分子通路。核心发现是，FTO通过m6A-YTHDF2依赖的方式稳定转录因子C-Jun，进而上调关键糖酵解酶PFKM的表达，从而驱动PDAC的发生与转移。此研究不仅创新性地将表观遗传调控与肿瘤代谢重编程联系起来，更揭示了FTO/C-Jun/PFKM轴作为PDAC潜在治疗靶点的重要临床价值。

---

## 38. TRIM8依赖的K63位泛素化PGK1通过与ACAT1的相互作用促进胃癌的糖酵解和血管生成。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184227](https://pubmed.ncbi.nlm.nih.gov/41184227)
**期刊：** Cell death & disease
**PMID：** 41184227
**DOI：** 10.1038/s41419-025-08015-y

### 第一部分 原文与翻译

**英文原标题：** TRIM8-dependent K63-ubiquitinated PGK1 promotes glycolysis and angiogenesis in gastric cancer via interaction with ACAT1.

**英文摘要原文：**
Glycolysis is crucial for promoting cancer progression. However, the precise mechanism underlying glycolysis regulating the angiogenic process remains to be defined. Here, we demonstrate that in human gastric cancer cells, the E3 ligase TRIM8 promotes the K63-linked ubiquitination of the glycolytic enzyme PGK1 and improves its stability, which leads to acetyltransferase ACAT1 recruitment, increased interaction of PGK1 with ACAT1, and subsequent PGK1 acetylation-dependent glycolytic activity. This activity facilitates PGK1-mediated glycolysis, lactate accumulation and triggers a significant increase in endothelial cell migration and tube formation, which ultimately accelerates tumor angiogenesis in gastric cancer. TRIM8 levels are positively correlated with tumor angiogenesis and poor prognosis in gastric cancer patients. These findings elucidate a novel mechanism underlying the upregulation of angiogenesis mediated by K63 ubiquitination-regulated glycolysis in tumor cells and provide a molecular basis for eliminating gastric cancer angiogenesis by targeting TRIM8-dependent PGK1 K63 ubiquitination.

**中文摘要译文：**
糖酵解在促进癌症进展中至关重要。然而，糖酵解调控血管生成过程的精确机制仍有待阐明。在此，我们证明在人类胃癌细胞中，E3连接酶TRIM8促进了糖酵解酶PGK1的K63连接泛素化并增强其稳定性，这导致乙酰转移酶ACAT1的招募、PGK1与ACAT1相互作用的增加，以及随后的PGK1乙酰化依赖性糖酵解活性。该活性促进了PGK1介导的糖酵解、乳酸积累，并引发内皮细胞迁移和管腔形成的显著增加，最终加速了胃癌中的肿瘤血管生成。在胃癌患者中，TRIM8的水平与肿瘤血管生成和不良预后呈正相关。这些发现阐明了肿瘤细胞中K63泛素化调控的糖酵解介导血管生成上调的新机制，并为通过靶向TRIM8依赖的PGK1 K63位泛素化来消除胃癌血管生成提供了分子基础。

### 第二部分 AI 大师评价

该研究旨在揭示胃癌中糖酵解调控血管生成的具体分子机制。研究发现，E3连接酶TRIM8通过对糖酵解关键酶PGK1进行K63位泛素化修饰，增强了其稳定性及与乙酰转移酶ACAT1的相互作用，进而提升了糖酵解活性，最终促进肿瘤血管生成。这项工作创新性地阐明了一条“TRIM8-PGK1泛素化-ACAT1-糖酵解-血管生成”的完整信号通路，不仅深化了对肿瘤代谢重编程与微环境互作的理解，也提示靶向TRIM8-PGK1轴可能成为抑制胃癌血管生成的潜在治疗策略。

---

## 39. JMJD3上调ALOX5驱动胃癌的恶性进展及伴随的铁死亡敏感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184226](https://pubmed.ncbi.nlm.nih.gov/41184226)
**期刊：** Cell death & disease
**PMID：** 41184226
**DOI：** 10.1038/s41419-025-08020-1

### 第一部分 原文与翻译

**英文原标题：** JMJD3 upregulates ALOX5 to drive malignancy and concomitant ferroptosis sensitivity in gastric cancer.

**英文摘要原文：**
Chemotherapy remains the cornerstone of gastric cancer (GC) treatment, with Oxaliplatin (OXA) being a critical first-line agent. However, chemotherapy resistance, compounded by increased stemness, poses a significant challenge in GC management. In this study, we demonstrate that JMJD3, encoded by KDM6B and catalyzing the demethylation of H3K27me3, is highly expressed in both GC tissues and patient-derived chemotherapy-resistant xenograft (PDX) models and contributes to increased malignancy and chemoresistance. Overexpression of JMJD3 enhanced stemness and chemoresistance in GC cells, while JMJD3 knockdown had opposite effects. Mechanistically, JMJD3 promotes GC cell stemness and chemoresistance by reducing H3K27me3 on the ALOX5 promoter, a histone modification associated with ALOX5 transcriptional activation. Tumorigenesis induced by N-methyl-N-nitrosourea (MNU) was reduced in mice with gastric epithelial cell-specific deletion of Kdm6b. Importantly, ALOX5 upregulation due to the elevated JMJD3 function sensitized GC cells to ferroptosis inducers. These findings suggest that JMJD3 plays a pivotal role in GC chemoresistance by modulating both stemness and ferroptosis sensitivity. Targeting JMJD3 may provide a novel therapeutic strategy for overcoming chemotherapy resistance, with ferroptosis inducers potentially offering a promising adjunctive treatment in GC.

**中文摘要译文：**
化学疗法仍然是胃癌（GC）治疗的基石，其中奥沙利铂（OXA）是一线关键药物。然而，化疗耐药性以及随之增强的干性给胃癌的治疗带来了巨大挑战。在本研究中，我们证明了由KDM6B编码并催化H3K27me3去甲基化的JMJD3，在胃癌组织及源自患者的耐药异种移植（PDX）模型中均高表达，并促进了恶性程度和化疗耐药性的增加。JMJD3的过表达增强了胃癌细胞的干性和化疗耐药性，而敲低JMJD3则产生相反的效果。机制上，JMJD3通过减少ALOX5启动子上的H3K27me3（一种与ALOX5转录激活相关的组蛋白修饰）来促进胃癌细胞的干性和化疗耐药性。在胃上皮细胞特异性敲除Kdm6b的小鼠中，由N-甲基-N-亚硝基脲（MNU）诱导的肿瘤发生过程受到抑制。重要的是，JMJD3功能增强导致的ALOX5上调使胃癌细胞对铁死亡诱导剂变得敏感。这些发现表明，JMJD3通过调节干性和铁死亡敏感性，在胃癌化疗耐药中扮演着关键角色。靶向JMJD3可能为克服化疗耐药提供一种新的治疗策略，而铁死亡诱导剂可能为胃癌提供一种有前景的辅助治疗方案。

### 第二部分 AI 大师评价

本研究旨在揭示组蛋白去甲基化酶JMJD3在胃癌化疗耐药及恶性进展中的作用机制。研究通过临床样本、PDX模型及细胞和动物实验发现，JMJD3通过表观遗传学方式上调ALOX5，从而增强了胃癌细胞的干性与化疗耐药性。其核心创新之处在于，揭示了JMJD3/ALOX5轴在驱动耐药的同时，也意外地增加了细胞对铁死亡的敏感性，为胃癌治疗提供了靶向JMJD3联合铁死亡诱导剂的新策略，具有重要的临床转化潜力。

---

## 40. 卡瑞利珠单抗联合化疗对比放化疗作为可切除食管鳞状细胞癌新辅助治疗的2期随机试验 (REVO)

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184224](https://pubmed.ncbi.nlm.nih.gov/41184224)
**期刊：** Nature communications
**PMID：** 41184224
**DOI：** 10.1038/s41467-025-64660-z

### 第一部分 原文与翻译

**英文原标题：** Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).

**英文摘要原文：**
Several studies have evaluated PD-1 inhibitors plus chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), but comparative data with chemoradiotherapy (CRT) remain limited. This multicenter, randomized, open-label, phase 2 non-inferiority trial (REVO, NCT05007145) assessed the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy (ICT) versus CRT in patients with resectable, locally advanced ESCC. A total of 104 patients were randomized to ICT (camrelizumab, nab-paclitaxel, cisplatin) or CRT (nab-paclitaxel, cisplatin, radiotherapy). The primary endpoint was pathologic complete response (pCR). ICT achieved a pCR rate of 32.7% versus 34.6% with CRT (rate ratio 0.94, 90% CI 0.6-1.49), demonstrating non-inferiority and meeting the pre-specified primary endpoint. Major pathologic response was observed in 42.3% of ICT patients and 57.7% of CRT patients, with R0 resection achieved in 100% of both groups. 1-year disease-free survival was 89.1% versus 78.2%, and 1-year overall survival was 100% versus 92.3% for ICT and CRT, respectively. Grade ≥3 treatment-related adverse events occurred in 19.2% of ICT patients and 33.3% of CRT patients, and surgical complications were reported in 31.1% and 35.9%, respectively. These findings indicate that ICT is a safe and effective neoadjuvant strategy for resectable ESCC with a more favorable safety profile.

**中文摘要译文：**
已有数项研究评估了PD-1抑制剂联合化疗作为局部晚期食管鳞状细胞癌（ESCC）的新辅助治疗方案，但与放化疗（CRT）的对比数据仍然有限。这项多中心、随机、开放标签、2期非劣效性试验（REVO, NCT05007145）旨在评估新辅助卡瑞利珠单抗联合化疗（ICT）对比CRT在可切除的局部晚期ESCC患者中的疗效与安全性。总计104名患者被随机分配至ICT组（卡瑞利珠单抗、白蛋白紫杉醇、顺铂）或CRT组（白蛋白紫杉醇、顺铂、放疗）。主要终点为病理学完全缓解（pCR）。ICT组的pCR率为32.7%，CRT组为34.6%（率比为0.94，90% CI为0.6-1.49），证明了ICT方案的非劣效性，达到了预设的主要终点。ICT组和CRT组的病理学主要缓解率分别为42.3%和57.7%，两组患者的R0切除率均为100%。ICT组与CRT组的1年无病生存率分别为89.1%和78.2%，1年总生存率分别为100%和92.3%。ICT组和CRT组发生≥3级治疗相关不良事件的比例分别为19.2%和33.3%，手术并发症的报告率分别为31.1%和35.9%。这些研究结果表明，对于可切除的ESCC，ICT是一种安全有效的新辅助治疗策略，且具有更优的安全性特征。

### 第二部分 AI 大师评价

本研究通过一项2期随机对照试验，首次直接比较了“免疫+化疗”（ICT）与传统“放化疗”（CRT）在新辅助治疗可切除食管鳞癌中的效果。研究核心发现，ICT方案在实现病理学完全缓解方面不劣于CRT，同时展现出更优的安全性（3级以上不良事件发生率更低）和良好的生存趋势。这项工作为临床提供了高质量的循证依据，表明去放疗的免疫化疗新辅助方案是治疗该类患者的一种有效且更安全的选择，可能对未来的治疗指南产生重要影响。

---

## 41. MET外显子14跳跃突变触发的调控网络全景图谱揭示RAS-ERK信号通路的关键作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41184222](https://pubmed.ncbi.nlm.nih.gov/41184222)
**期刊：** Cell death & disease
**PMID：** 41184222
**DOI：** 10.1038/s41419-025-08086-x

### 第一部分 原文与翻译

**英文原标题：** Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway.

**英文摘要原文：**
The MET exon 14 skipping mutation (named METex14Del) described in lung cancer leads to prolonged activation of signaling pathways and aberrant cell responses, but the link between HGF signaling and cell responses remains unclear. A putative lung cancer regulatory network of influential transcription factors was constructed from the transcriptomes of lung cancer cell lines. Transcriptomic data from METex14Del-expressing cells, stimulated or not by HGF, were mapped onto this lung cancer reference network and revealed activation of a major regulatory node composed mainly by the highly influential transcription factors ETS1, FOSL1 and SMAD3. HGF activation of METex14Del receptor induced the expression and phosphorylation of these three master regulators and the expression of their predicted target genes involved in migration and invasion. All these molecular and biological effects were inhibited by trametinib, a MEK inhibitor, which was potentiated by combination with capmatinib, a MET inhibitor. New mapping with transcriptomic data from trametinib-treated METex14Del cells validated the key role of the RAS-ERK pathway signaling in the activation of ETS1, FOSL1 and SMAD3 regulators and the induction of their target genes in HGF-activated METex14Del receptor. Thus, we report an original and powerful strategy to uncover key regulators, including transcription factors that have not been widely described in METex14Del signaling, such as SMAD3. These factors are activated by specific signaling pathways and could provide a novel therapeutic strategy involving a combination of receptor and signaling inhibitors.

**中文摘要译文：**
肺癌中描述的MET外显子14跳跃突变（命名为METex14Del）导致信号通路的持续激活和异常的细胞反应，但肝细胞生长因子（HGF）信号与细胞反应之间的联系仍不清楚。研究人员利用肺癌细胞系的转录组数据，构建了一个由关键转录因子组成的肺癌推定调控网络。将经HGF刺激或未经刺激的METex14Del表达细胞的转录组数据映射到此肺癌参考网络上，结果揭示了一个主要调控节点的激活，该节点主要由高影响力的转录因子ETS1、FOSL1和SMAD3组成。HGF对METex14Del受体的激活诱导了这三个主调控因子的表达和磷酸化，以及它们预测的、与迁移和侵袭相关的靶基因的表达。所有这些分子和生物学效应均可被MEK抑制剂曲美替尼所抑制，并且与MET抑制剂卡马替尼联合使用时效果增强。利用经曲美替尼处理的METex14Del细胞的转录组数据进行的新映射，验证了RAS-ERK通路信号在HGF激活的METex14Del受体中对ETS1、FOSL1和SMAD3调控因子的激活及其靶基因诱导中的关键作用。因此，我们报告了一种新颖而强大的策略，用以揭示关键的调控因子，包括在METex14Del信号传导中尚未被广泛描述的转录因子，如SMAD3。这些因子由特定的信号通路激活，并可能为开发联合使用受体和信号抑制剂的新型治疗策略提供依据。

### 第二部分 AI 大师评价

本研究旨在全面绘制肺癌中由MET外显子14跳跃突变（METex14Del）触发的基因调控网络。研究通过分析转录组数据，成功鉴定出ETS1、FOSL1和SMAD3是该网络中的核心调控节点，并证实RAS-ERK信号通路在其激活过程中发挥着关键作用。此项工作的创新之处在于，通过一种新颖的生物信息学策略，揭示了SMAD3等以往未被充分认识的转录因子在METex14Del信号传导中的重要性。这些发现不仅深化了对METex14Del驱动的肿瘤生物学行为的理解，也为联合使用MET抑制剂和MEK抑制剂（如卡马替尼与曲美替尼）治疗相关肺癌提供了坚实的理论基础和新的治疗策略。

---

## 42. VEXAS综合征中炎症与髓系偏向的独立机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41183570](https://pubmed.ncbi.nlm.nih.gov/41183570)
**期刊：** Nature
**PMID：** 41183570
**DOI：** 10.1038/s41586-025-09815-0

### 第一部分 原文与翻译

**英文原标题：** Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome.

**英文摘要原文：**
Somatically acquired mutations in the E1 ubiquitin-activating enzyme UBA1 within hematopoietic stem and progenitor cells (HSPCs) were recently identified as the cause of the adult-onset autoinflammatory syndrome VEXAS (vacuoles, E1 enzyme, X linked, autoinflammatory, somatic). UBA1 mutations in VEXAS lead to clonal expansion within the HSPC and myeloid, but not lymphoid, compartments. Despite its severity and prevalence, the mechanisms whereby UBA1 mutations cause multiorgan autoinflammation and hematologic disease are unknown. Here, we employ somatic gene editing approaches to model VEXAS-associated UBA1 mutations in primary macrophages and HSPCs. Uba1-mutant macrophages exposed to inflammatory stimuli underwent aberrant apoptotic and necroptotic cell death mediated by Caspase-8 and RIPK3-MLKL, respectively. Accordingly, in mice challenged with TNF or LPS, the UBA1 inhibitor TAK-243 exacerbated inflammation in a RIPK3-Caspase-8-dependent manner. In contrast, Uba1 mutation in HSPCs induced an unfolded protein response and myeloid bias independently of RIPK3-Caspase-8. Mechanistically, aberrant cell death of Uba1-mutant macrophages coincided with a kinetic defect in Lys63/Met1 (i.e., linear) polyubiquitylation of inflammatory signaling complexes. Collectively, our results link VEXAS pathogenesis with that of rarer monogenic autoinflammatory syndromes; highlight specific ubiquitin-associated defects stemming from an apical mutation in the ubiquitylation cascade; and support therapeutic targeting of the inflammatory cell death axis in VEXAS.

**中文摘要译文：**
最近，在造血干/祖细胞（HSPCs）中发现的E1泛素激活酶UBA1的体细胞获得性突变，被确定为成人发病的自身炎症综合征——VEXAS（空泡、E1酶、X连锁、自身炎症、体细胞）的病因。VEXAS综合征中的UBA1突变导致HSPC和髓系（而非淋巴系）细胞区室的克隆性扩增。尽管该病严重且普遍，但UBA1突变导致多器官自身炎症和血液系统疾病的机制尚不清楚。本研究中，我们采用体细胞基因编辑方法，在原代巨噬细胞和HSPCs中模拟与VEXAS相关的UBA1突变。暴露于炎症刺激下的Uba1突变型巨噬细胞，会发生分别由Caspase-8和RIPK3-MLKL介导的异常细胞凋亡和坏死性凋亡。相应地，在经TNF或LPS攻击的小鼠中，UBA1抑制剂TAK-243以RIPK3-Caspase-8依赖的方式加剧了炎症反应。相反，HSPCs中的Uba1突变则独立于RIPK3-Caspase-8，诱导了未折叠蛋白反应和髓系偏向。从机制上看，Uba1突变型巨噬细胞的异常死亡与炎症信号复合物的Lys63/Met1（即线性）多聚泛素化的动力学缺陷相吻合。总而言之，我们的研究结果将VEXAS的发病机制与更罕见的单基因自身炎症综合征联系起来；突显了源于泛素化级联反应顶端突变的特定泛素相关缺陷；并支持将炎症性细胞死亡轴作为VEXAS的治疗靶点。

### 第二部分 AI 大师评价

该研究旨在揭示VEXAS综合征中UBA1突变如何同时引发自身炎症和髓系偏向这两种核心病理表现。研究团队创新性地利用体细胞基因编辑技术，在巨噬细胞和造血干/祖细胞中分别构建突变模型，精准剖析了不同细胞谱系中的致病机制。其关键发现是，炎症与髓系偏向由两条独立通路驱动：突变在巨噬细胞中通过Caspase-8/RIPK3通路触发炎症性细胞死亡，而在造血干/祖细胞中则独立地诱导未折叠蛋白反应与髓系偏向。这项工作不仅深刻揭示了VEXAS综合征复杂的发病机理，更具临床指导意义的是，它提示炎症和血液学异常可能需要不同的治疗策略，并明确指出了炎症性细胞死亡通路是治疗该病炎症症状的潜在靶点。

---

## 43. 局限性尤文肉瘤患者的分子特征分析可用于预后判断：来自儿童肿瘤协作组的一项报告

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41183255](https://pubmed.ncbi.nlm.nih.gov/41183255)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41183255
**DOI：** 10.1200/JCO-25-00157

### 第一部分 原文与翻译

**英文原标题：** Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

**英文摘要原文：**
PURPOSE: Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group (COG) biology study AEWS18B1-Q was to molecularly characterize patients with localized EWS on prospective modern-day trials.

PATIENTS AND METHODS: We analyzed clinical and molecular features from patients with localized EWS enrolled on frontline COG trials. All patients had available formalin-fixed paraffin-embedded (FFPE) tissue, frozen tissue, or whole-genome-amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in  and . Available tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses.

RESULTS: Three hundred fifty-one patients had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 patients (80.3%). Pathogenic mutations in  and  were identified in 5.1% and 7.6% of patients, respectively. A total of 63.1% of patients were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with  mutation (5-year cumulative incidence of relapse 43%, 95% CI [17% to 67%]  22%, 95% CI [17% to 27%]; Gray's test  = .039),  mutation (53%, 95% CI [29% to 73%]  21%, 95% CI [16% to 26%];  < .001), and recurrent CNAs (30%, 95% CI [22% to 37%]  16%, 95% CI [9% to 24%];  = .005). In a multivariable analysis,  mutation was the only molecular biomarker that remained prognostic.

CONCLUSION: This is a prospective validation of the molecular prognostic features of patients with localized EWS receiving standard-of-care therapy on therapeutic clinical trials. Building on previous work, patients with  mutations were at high risk of relapse.

**中文摘要译文：**
目的：在局限性尤文肉瘤（EWS）中，识别与治疗反应和耐药相关的特定亚组仍然是一项挑战。儿童肿瘤协作组（COG）的生物学研究AEWS18B1-Q的主要目标，是对参加前瞻性现代临床试验的局限性EWS患者进行分子特征分析。

患者与方法：我们分析了入组一线COG临床试验的局限性EWS患者的临床和分子特征。所有患者均有可用的福尔马林固定石蜡包埋（FFPE）组织、冰冻组织或全基因组扩增材料。我们通过测序技术来鉴定典型的融合基因、复发性拷贝数变异（CNAs）以及TP53和STAG2基因的改变。对可用的组织样本进行了STAG2蛋白表达缺失的分析。在单变量和多变量分析中，评估了分子特征与累积复发率之间的关联。

结果：共有351名患者拥有足够的组织样本，其中大多数样本提取自两张FFPE切片。在282名患者（80.3%）中鉴定出了EWS的典型融合基因。分别在5.1%和7.6%的患者中发现了TP53和STAG2的致病性突变。总计63.1%的患者被发现存在复发性CNAs。在单变量分析中，携带TP53突变（5年累积复发率 43%，95% CI [17% to 67%] vs 22%，95% CI [17% to 27%]；Gray's检验 P = .039）、STAG2突变（53%，95% CI [29% to 73%] vs 21%，95% CI [16% to 26%]；P < .001）以及复发性CNAs（30%，95% CI [22% to 37%] vs 16%，95% CI [9% to 24%]；P = .005）的患者，其累积复发率均有升高。在多变量分析中，STAG2突变是唯一保留预后价值的分子生物标志物。

结论：本研究是对接受标准化疗方案的局限性EWS患者分子预后特征的一项前瞻性验证，这些患者均参与了治疗性临床试验。基于既往研究，携带STAG2突变的患者具有高复发风险。

### 第二部分 AI 大师评价

该研究是一项来自儿童肿瘤协作组（COG）的大规模前瞻性研究，旨在探索局限性尤文肉瘤的分子预后标志物。研究团队通过对351例接受标准化疗的患者样本进行测序分析，系统评估了基因融合、拷贝数变异及关键基因（如TP53和STAG2）突变与复发风险的关联。其核心发现是，尽管多种分子改变与预后相关，但在多变量分析中，仅STAG2突变是独立的、强有力的不良预后因素。这项研究的价值在于前瞻性地验证了STAG2突变的预后意义，为未来实现精准的风险分层和个体化治疗策略提供了高级别证据。

---

## 44. 机械取栓联合抗凝与单纯抗凝治疗急性中高危肺栓塞的随机对照试验：STORM-PE试验的主要结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41183181](https://pubmed.ncbi.nlm.nih.gov/41183181)
**期刊：** Circulation
**PMID：** 41183181
**DOI：** 10.1161/CIRCULATIONAHA.125.077232

### 第一部分 原文与翻译

**英文原标题：** Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.

**英文摘要原文：**
BACKGROUND: Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right-to-left-ventricular (RV/LV) diameter ratio and are at risk of early clinical decompensation and mortality. Reperfusion therapy aims to rapidly relieve acute RV pressure overload and normalize hemodynamics. STORM-PE is the first reported randomized controlled trial (RCT) to test the efficacy and evaluate the safety of mechanical thrombectomy (MT), specifically computer assisted vacuum thrombectomy (CAVT) with anticoagulation (AC) compared to AC alone.

METHODS: STORM-PE is an international RCT with 1:1 randomization to CAVT with AC or AC alone. Eligible adults had acute onset (symptoms ≤14 days), intermediate-high risk PE, and were normotensive, with an RV≤LV ratio ≥1.0 on computed tomography pulmonary angiography and elevated cardiac biomarkers. The primary endpoint analysis tested for a difference between groups for the change in RV/LV ratio at 48 hours, assessed by a blinded independent imaging core laboratory. Secondary endpoints included major adverse events (MAE) within 7 days (a composite of clinical deterioration necessitating rescue therapy, PE-related mortality, symptomatic recurrent PE, and major bleeding), adjudicated by an external clinical events committee. Additional outcomes included change in vital signs and core lab assessed PA obstruction at 48 hours.

RESULTS: A total of 100 patients enrolled across 22 sites were randomized to CAVT (N=47) or AC alone (N=53). Baseline characteristics were comparable between arms. At 48 hours, mean reduction in RV/LV ratio was greater for CAVT (0.52±0.37) than AC (0.24±0.40), a difference of 0.27 (95% CI, 0.12, 0.43; <0.001). Refined modified and modified Miller score exhibited greater changes for CAVT than AC at 48 hours (<0.001). Early normalization of vital signs within 48 hours was more frequent after CAVT. The MAE rate within 7 days was not different between groups (CAVT 4.3% vs AC 7.5%, =0.681). Two PE-related deaths occurred in the CAVT arm.

CONCLUSIONS: CAVT was superior to AC alone in reducing RV/LV ratio within 48 hours in intermediate-high risk PE patients, accompanied by earlier normalization of vital signs and comparable MAE rates to AC.

**中文摘要译文：**
背景：中高危肺栓塞（PE）患者的右心室与左心室（RV/LV）直径比值升高，并存在早期临床失代偿和死亡的风险。再灌注治疗旨在迅速缓解急性右心室压力超负荷并使血流动力学正常化。STORM-PE是首个报道的随机对照试验（RCT），旨在检验机械取栓（MT），特别是计算机辅助真空血栓清除术（CAVT）联合抗凝（AC）相较于单纯AC治疗的有效性并评估其安全性。

方法：STORM-PE是一项国际性RCT，将患者按1:1的比例随机分配至CAVT联合AC组或单纯AC组。符合条件的成年患者为急性发作（症状≤14天）、中高危PE、血压正常，且计算机断层肺动脉造影显示RV/LV比值≥1.0并伴有心脏生物标志物升高。主要终点分析旨在检验两组间在48小时时RV/LV比值变化量的差异，该指标由一个独立的、设盲的影像核心实验室进行评估。次要终点包括7天内的主要不良事件（MAE）（其为需要补救治疗的临床恶化、PE相关死亡率、有症状的复发性PE和主要出血的复合终点），由一个外部临床事件委员会进行裁定。其他结局包括生命体征的变化以及核心实验室评估的48小时时肺动脉阻塞情况。

结果：共有来自22个中心的100名患者入组，并被随机分配至CAVT组（N=47）或单纯AC组（N=53）。两组的基线特征具有可比性。在48小时时，CAVT组的RV/LV比值平均下降幅度（0.52±0.37）大于AC组（0.24±0.40），差值为0.27（95% CI, 0.12, 0.43; <0.001）。在48小时时，改良的和精细改良的Miller评分在CAVT组的变化也大于AC组（<0.001）。CAVT治疗后，生命体征在48小时内早期恢复正常的情况更为常见。7天内的MAE发生率在两组间无显著差异（CAVT组4.3% vs AC组7.5%，p=0.681）。CAVT组发生了两例与PE相关的死亡事件。

结论：对于中高危PE患者，CAVT在48小时内降低RV/LV比值方面优于单纯AC治疗，同时伴随着生命体征的更早正常化，且MAE发生率与AC相当。

### 第二部分 AI 大师评价

本研究是首个针对中高危肺栓塞的机械取栓（具体为计算机辅助真空血栓清除术）随机对照试验，旨在评估其相较于标准抗凝治疗的有效性与安全性。研究通过一项国际多中心RCT发现，机械取栓在48小时内能更显著地改善反映右心功能负荷的RV/LV比值，并加速生命体征的恢复。尽管该研究在影像学替代终点上取得了阳性结果，但两组在7天内的主要不良临床事件发生率上无显著差异，这提示我们需要更大规模的临床试验来最终确立其在改善患者硬终点事件（如死亡率）方面的价值。

---

## 45. 靶向ATM-TGS1-BRCA1信号轴可克服胰腺导管腺癌的基因毒性治疗耐药

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41183146](https://pubmed.ncbi.nlm.nih.gov/41183146)
**期刊：** Cancer research
**PMID：** 41183146
**DOI：** 10.1158/0008-5472.CAN-25-1435

### 第一部分 原文与翻译

**英文原标题：** Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma.

**英文摘要原文：**
Pancreatic adenocarcinoma (PAAD) remains one of the most lethal malignancies, primarily due to its robust resistance to genotoxic therapies, such as chemotherapy and radiotherapy. Understanding the mechanisms underlying this resistance is essential to improve clinical outcomes. Here, we identified trimethylguanosine synthase 1 (TGS1), previously known for its role in RNA modification, as a critical mediator of homologous recombination (HR) repair that specifically contributes to resistance in PAAD. TGS1 was significantly overexpressed in PAAD tissues, correlating strongly with advanced disease stages, therapy resistance, and poor patient prognosis. Following DNA damage, ATM kinase phosphorylated TGS1 at serine residues S389 and S531, which mediated its direct interaction with BRCA1 and subsequent recruitment of BRCA1 to DNA damage sites. The phosphorylation-dependent interaction enhanced HR repair efficiency, enabling cancer cells to survive genotoxic stress. Depletion or pharmacological inhibition of TGS1 induced HR deficiency and markedly enhanced sensitivity to DNA-damaging agents, particularly PARP inhibitors, in PAAD cell lines in vitro and in both cell line-derived and patient-derived xenograft models in vivo. Collectively, these findings uncover an ATM-TGS1-BRCA1 signaling axis that promotes DNA repair and resistance to genotoxic therapies in pancreatic cancer, positioning TGS1 as a promising predictive biomarker and therapeutic target to enhance treatment efficacy.

**中文摘要译文：**
胰腺导管腺癌（PAAD）仍然是致死率最高的恶性肿瘤之一，主要原因是其对化疗和放疗等基因毒性疗法具有强大的耐药性。理解这种耐药性背后的机制对于改善临床结局至关重要。在本研究中，我们鉴定出三甲基鸟苷合酶1（TGS1）是同源重组（HR）修复的关键介导因子，它特异性地导致了PAAD的耐药性，而该酶以往被认为在RNA修饰中发挥作用。TGS1在PAAD组织中显著过表达，并与疾病晚期、治疗耐药和患者不良预后密切相关。在DNA损伤后，ATM激酶会磷酸化TGS1的丝氨酸残基S389和S531，这介导了TGS1与BRCA1的直接相互作用，并随后将BRCA1招募至DNA损伤位点。这种磷酸化依赖性的相互作用增强了HR修复效率，使癌细胞能够在基因毒性应激下存活。在体外PAAD细胞系以及体内的细胞源性和患者源性异种移植模型中，敲除或药物抑制TGS1会诱导HR缺陷，并显著增强细胞对DNA损伤药物（尤其是PARP抑制剂）的敏感性。总之，这些发现揭示了一条促进DNA修复和胰腺癌基因毒性治疗耐药的ATM-TGS1-BRCA1信号轴，将TGS1定位为一个有前景的、可用于提高治疗效果的预测性生物标志物和治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示胰腺癌基因毒性治疗耐药的关键机制。研究团队通过分子生物学实验、细胞系及异种移植模型，创新性地发现并阐明了一条全新的ATM-TGS1-BRCA1信号轴。其核心发现是，先前被认为参与RNA修饰的TGS1蛋白，在DNA损伤后被ATM磷酸化，进而招募BRCA1以促进同源重组修复，最终导致治疗耐药。这项工作不仅为理解胰腺癌的耐药性提供了新视角，更重要的是将TGS1确立为一个极具潜力的治疗靶点和预后生物标志物，为开发联合治疗策略（如TGS1抑制剂联合PARP抑制剂）以克服胰腺癌耐药提供了坚实的理论基础。

---

速递结束，祝您工作愉快！